

**Taking
back from
cancer**



**ANNUAL
REPORT**

2022

 **Irish
Cancer
Society**

Cancer takes so much from people every day. Together, as a community, we are bringing forward the day when cancer can take no more.

JARUSHKA

Read her **Treating cancer** story on page 30



PAUL

Read his **Healthy living** story on page 18



Read his **Catching cancer early** story on page 24

TOM

CONTENTS

Vision, mission and values	2
Message from the Chair and CEO	4
Highlights 2022	6
~~~~~	
Report of the Board	11
Strategic review	12
Introduction	12
Priority one: Healthy living	14
Paul's story	18
Priority two: Catching cancer early	20
Tom's story	24
Priority three: Treating cancer	26
Jarushka's story	30
Priority four: Living well	32
Donna-Marie's story	36
Priority five: End-of-life care	38
Brid's story	42
Structured for impact	44
How we work	48
Fundraising review	54
Financial review	58
Structure, governance and management	62
Our Board	68
~~~~~	
Financial statements	73
Independent auditor's report	74
Statement of financial activities	77
Balance sheet	78
Statement of cash flows	79
Notes to the financial statements	80
Reference and administrative details	102
~~~~~	

# 1,700

health checks at the Your Health Matters roadshow



# €4.7m

raised on Daffodil Day 2022



## DONNA-MARIE

Read her **Living well** story on page 36



Read her **End-of-life care** story on page 42

# BRID



# VISION, MISSION, VALUES

## VISION

By 2025, three out of four Irish cancer patients will survive their diagnosis and everyone affected by the disease will have access to world-class treatment, care and support.

In future, no one in Ireland will die from cancer.

## MISSION

The Irish Cancer Society is a community of patients, survivors, volunteers, supporters, health and social care professionals and researchers.

Together, we are working to save lives and improve the lives of people affected by cancer in Ireland.





# VALUES

## **We are compassionate and caring.**

Everyone's cancer journey is individual and we reflect that in everything we do. From the time you are diagnosed, right through to treatment and beyond, we provide personal support that is right for you.

## **We are inclusive.**

Whoever you are and wherever you come from, we are here for you. We are working hard to ensure that everyone in Ireland has the same access to care and support during their cancer journey.

## **We demand excellence from ourselves and others.**

We are constantly demanding more of ourselves and others on your behalf. We always believe there is room for improvement and we strive for excellence in all we do. Our services and decisions are informed by best quality knowledge, data and expertise.

## **We value collaboration.**

Collaborating and working in partnership with world class medical professionals, researchers, organisations and supporters helps us to deliver more. We want to be inspired and to improve by challenging ourselves and by benchmarking ourselves against world-class results.

We build alliances and work with local communities and global partners to deliver best results.

## **We are accountable and transparent.**

We work to the highest standards of governance and financial management. This means we are honest, ethical and efficient in our work. We hold ourselves accountable for the delivery of our goals and objectives.

## **We support sustainability.**

We care about our communities and environment. We strive to be a sustainable organisation and minimise our impact on the world around us.

# MESSAGE FROM OUR CHAIR AND CEO

Daffodil Day 2022 was a day of hope and optimism. It was the day we took back from cancer. After two years of COVID-19 restrictions, our community was back on the streets of Ireland raising awareness and spirits and, of course, raising vital funds.

BRID



AVERIL

Thanks to volunteers and supporters up and down the country, Daffodil Day 2022 was the second most successful in the Society's history, raising an incredible €4.7 million and allowing us to meet the challenges that 2022 brought.

Although 2022 was not easy, our hope and determination, encapsulated by Daffodil Day, prevailed. As a community, we worked tirelessly to face new challenges and continue to take back from cancer.

As much as we wished to move past the pandemic, the legacy of COVID-19 remained. Patients and families needed emotional and psychological support, as they dealt with the impact of two years of pandemic restrictions, and ongoing worry about reopening.

Our nurses on the Support Line and in Daffodil Centres were there to support and advise. We saw a 22% increase in the number of support conversations, with noticeable

higher levels of distress. In response, we increased the counselling we provided and funded, supporting 3,250 patients during the year.

In 2020, we highlighted concerns that the pandemic could undo progress made in cancer detection and care. Each year since then those concerns continue. In late 2021, the National Cancer Registry of Ireland (NCRI) figures indicated that as many as one in eight cancers predicted to be diagnosed in 2020 were not diagnosed. Because of COVID-19 cancers were being caught at a later stage, or not at all.

In response, we stepped up our efforts to advance the early detection and diagnosis of cancer. Our 'Your Health Matters Roadshow' went nationwide, visiting 20 locations over 46 days, offering people information about cancer signs and symptoms and a free, nurse-led health check. Staff and volunteers engaged with over 18,000 people through these Roadshows, and nurses conducted

almost 1,700 health checks. We continued our awareness campaigns, reaching and engaging more people, and we continually advocated for Government action, highlighting the crisis and impact of delayed diagnosis. Early detection will be a significant focus for us for 2023, we need to win back the progress lost.

2022 also saw unexpected global and local challenges, which impacted patients and our work, in particular the invasion and brutal war in Ukraine. As we write this, in April 2023, Ireland has welcomed some 70,000 Ukrainians, including children and adults with cancer who need to continue their treatment and care here. We stepped up immediately, putting in place services to support people through an incredibly difficult time.

This response was in line with our values: we are an inclusive organisation, here for everyone. We are proud of our efforts to ensure people of all backgrounds have access to our supports and services,



and to do what we can to reduce health inequalities. This is why we entered into a partnership with the Capuchin Day Centre and Safety Net Primary Care to support users of the Centre's food aid service, who may be homeless or otherwise marginalised. We will continue our work in 2023 to ensure that we are there for everyone affected by cancer in Ireland.

One of the other major challenges faced in 2022 was the cost of living crisis. Increased costs mean that the financial burden of cancer is even greater for patients, families and survivors. Improving survivorship and reducing the burden of cancer is a strategic priority for the Society, and in 2022 we redoubled our efforts. We advocated tirelessly to highlight the Real Cost of Cancer, and to propose tangible changes that Government can make. After years of campaigning, we were particularly pleased to see autumn's Budget announcement that hospital in-patient charges will be abolished from April 2023.

We also increased our supports and services for people affected by cancer, to reduce the practical and financial burden. We introduced a new Practical Support and Financial Solutions service, where trained specialists work with patients and families to provide support and solutions on issues ranging from tenancy to childcare.

Our volunteer driver service grew significantly in 2022, with volunteers providing patients with 17,000 drives (an increase of almost one-third on 2021). We have seen this demand continue into 2023 and expect these services to grow even further in the year ahead as patients continue to face financial and practical pressures.

Cancer can be devastating at any age, but for children and teenagers affected by a cancer diagnosis the impact is particularly stark. In 2022, we continued to increase our supports for children, adolescents and young people (CAYA) and

their families. As well as funding counselling, fertility preservation, play therapy, and providing advice and information, we ensured that we could be with children and families, when and where they needed us. Our children's cancer nurse was on-site in Children's Health Ireland (CHI) Crumlin to provide advice and support. We partnered with Barretstown to run special camps for families and young adults to provide care and support – and fun – to people affected by childhood cancer.

Despite the many challenges that 2022 brought, we kept our focus on our long-term vision: of a future where everyone lives, and lives well, with and beyond cancer. Cancer research plays an important part in achieving that vision. It is the hope on the horizon. The Irish Cancer Society is the largest voluntary funder of cancer research in Ireland and in 2022, we invested a further €3.7 million in new cancer research. This included survivorship research programmes such as our Men's Health Initiative (the Liam Mc Trial) and the Women's Health Initiative, which expanded to new sites in 2022. We funded increased numbers of patients on cancer trials through our support for Cancer Trials Ireland, and we invested in research and researchers across the country to support a vibrant and talented research community in Ireland.

As a charity, reliant on the generosity of the public, 2022 has challenged us as an organisation. We are managing rising costs, in the face of increased need for our services and supports. We never cease to be overwhelmed by the generosity of the public, corporate partners, and donors, who continue to support the Society, and those affected by cancer, even while facing a cost of living crisis. This generosity fills us with hope and confidence. It reminds us that we are part of our national community, there for people affected by cancer. It gives us the confidence that we can, and will, take back from cancer.

## Despite the many challenges that 2022 brought, we kept our focus on our long-term vision: of a future where everyone lives, and lives well, with and beyond cancer.

While new and increasing crises challenged our hope and optimism at times during 2022, as a community, we persevered, we responded and we adapted. We can only do so with the wonderful and generous support, for which we are forever grateful.

For your role in the work of the Irish Cancer Society – as a patient, a survivor, a volunteer, a supporter, a donor, a partner, a clinician, a researcher, a member of our dedicated staff – thank you. Because of you we take back from cancer, not just on Daffodil Day, but every day.



**Brid Horan**  
Chair



**Averil Power**  
CEO

# HIGHLIGHTS 2022

## Daffodil Day 2022

Daffodil Day 2022 was a momentous occasion, as supporters and volunteers across Ireland took to the streets for the first time since 2019. We were delighted to be able to paint Ireland yellow once again, and mark the day that we take back from cancer. Thanks to the incredible efforts of supporters across the country, and the generosity of the public, Daffodil Day 2022 raised over €4.7 million: the second highest amount ever raised through Daffodil Day in the Society's history!



**Top:** volunteer collectors were back on the streets for Daffodil Day 2022; **Bottom:** The launch of the first Daffodil Bench in Skerries, Co. Dublin.





Left (Top and Bottom): Irish Cancer Society staff and politicians at the Care for Your Pair Oireachtas members' briefing in October; Top right: the launch of the Irish Cancer Society Liam Mc Trial in Cork; Bottom right: volunteers and staff celebrating the volunteer driver service win at the Volunteer Ireland Awards.

## Care for Your Pair

In October, we marked Breast Cancer Awareness month by encouraging people across Ireland to "Care for Your Pair": taking care of their own breasts, and encouraging their friends to do the same. The whole country got involved: Big Pink Breakfasts took place across the country, Centra stores ran events and in-store activity, and social media lit up with celebrities, influencers and the public sharing the message. Primark launched a nightwear range with Sarah Harding's former band-mates, in honour of the Girls Aloud singer who sadly died from breast cancer in 2021. We were honoured that the Irish Cancer Society was selected to receive 50% of the sales from this range.

## Award-winning volunteer drivers

In 2022, over 1,000 volunteers drove patients to and from their chemotherapy appointments providing invaluable practical support to people undergoing cancer treatment. In September, we were so proud to see our volunteer drivers recognised at the Volunteer Ireland Awards, taking home the award for best large group. The award recognised the dedication of the drivers and the impact that they have, every day, for people affected by cancer.

## Irish Cancer Society Liam Mc Trial

The Irish Cancer Society Liam Mc Trial (short for Linking In with Advice and supports for Men with Metastatic Cancer) is trialling a first-of-its-kind programme of supports and services for men affected by cancer. The programme is designed to help men deal with the physical and emotional burdens of cancer, so that they can live full and fulfilling lives during and after cancer treatment.

The programme is a result of funding awarded by the Irish Cancer Society to the research team in University College Cork and Cork University Hospital.

## Daffodil benches

In November, we unveiled our first Daffodil Bench in Skerries, Co Dublin. The brightly coloured bench is a symbol of hope and support for anyone facing a cancer diagnosis, and we aim to have 50 benches in place by the end of 2023. Each bench has a plaque with a QR code linking to information about Irish Cancer Society supports and services. The project is a partnership between the Irish Cancer Society, Irish Men's Sheds Association and City and County Councils across the country.




## Capuchin Day Centre partnership

In 2022, we launched a partnership with the Capuchin Day Centre and Safety Net Primary Care to support users of the Centre's food aid service, who may be homeless or otherwise marginalised. Irish Cancer Society nurses, Agnes and Tracy, attend the Capuchin Day Centre to carry out health checks, discuss signs and symptoms of cancer, and refer people to additional health services they may need. 156 health checks have been completed in 2022 since we started in the summer, and we'll continue the partnership into 2023.

## Leave our Leave

In June the Society and cancer survivors Erica Tierney, Mary Canavan and Emma McGuinness, launched our campaign for change to allow women defer maternity leave following a cancer diagnosis while pregnant. We called on Government to change current legislation that prevents women from deferring their maternity leave until they have finished their treatment and can properly bond with their new baby. This unfair legislative anomaly affects approximately 60 women each year and only emerges once they try to pause their maternity leave while they are being treated for cancer.



Top right: Advocates Emma, Erica and Mary with Irish Cancer Society Director of Advocacy and External Affairs, Rachel Morrogh, at the launch of our Leave our Leave campaign.

Bottom right: Our pre-budget submission called on Government to cut the costs of cancer.

## Cut the Costs

We continued to work tirelessly to highlight the cost of cancer, and urge Government to cut the costs, including through our pre-budget submission campaign. We are grateful to all of the patients, families and survivors who bravely shared their stories of the financial burden of a cancer diagnosis. Following our advocacy, Budget 2023 had the momentous announcement that hospital in-patient charges would finally be abolished, and this will come into effect from April 2023.



# 2022 IN NUMBERS

16,950

Drives to and from cancer treatment provided

↑ Up 30% from 2021

1,700

Health checks conducted at our early detection roadshow

↑ Up 54% from 2021

139

Cancer researchers funded

↑ Up 3% from 2021

6

Camps run, in partnership with Barretstown, for families and young people affected by childhood cancer

New in 2022

2,150

Participants in patient education

↑ Up 15% from 2021

1.3 million

Visits to cancer.ie¹

↓ Down 20% from 2021

21,500

Daffodil Centre and Support Line support conversations with a cancer nurse²

↑ Up 22% from 2021

1,000

New patients participating in cancer trials with Cancer Trials Ireland³

↑ Up 15% from 2021

2,050

Cancer patients supported by our night nursing service⁴

↓ Down 9% from 2021

16,200

Counselling sessions provided⁵

↑ Up 12% from 2021

€3.7 million

Investment in new cancer research

↓ Down 5% from 2021

3,000

Active volunteers⁶

↑ Up 20% from 2021

All numbers greater than 500 are rounded to the nearest 50.

1. 2021 saw record numbers visiting cancer.ie to make donations following our Late Late Show Daffodil Day appeal.
2. Daffodil Centre nurses also conduct group and one-to-one patient education sessions, which are separately included under "Participants in patient education", and cancer awareness sessions which are not included in this figure.
3. This is in addition to the thousands of patients in treatment or follow-up on trials which commenced in earlier years.
4. As pandemic restrictions lifted, the number of patients supported by the night nursing service returned to pre-pandemic levels.
5. Includes sessions provided through our direct network of remote counsellors, and counselling sessions delivered in the community through our funding.
6. This does not include the thousands of Daffodil Day street sale volunteers who were back on the streets in 2022, or our shop volunteers (who are not yet recorded on our volunteer database).



## Our priorities

### Healthy living

#### Fewer preventable cancers

We will influence Government policy and laws so that everyone has the best chance of living a life free from cancer. We will invest in research that uncovers new ways to prevent cancer. We will provide advice to those who need it.

### Catching cancer early

#### More cancers caught early

We will give people the best chance of surviving cancer. We will lead advocacy campaigns, innovate services, fund research, and work in partnerships that will eliminate the survival gap between Ireland and other European countries.

### Treating cancer

#### World-class cancer treatment for everyone

We will lobby Government so that all cancer patients are given timely access to treatments that will work best for them. We will reduce the fear of cancer through our support services and invest in research that has the potential to transform lives.

### Living well

#### Living well after treatment

We will make sure the emotional, physical, financial and practical needs of those who have undergone cancer treatment are met. We will provide services that will directly support people, so they are better able to cope with the impact of cancer. We will undertake research that will help us improve cancer patients' quality of life.

### End-of-life care

#### Holistic support for people dying from cancer

We will ensure people dying from cancer have access to the full range of supports needed by them and their families. We will drive changes from Government that will mean more people can die at home. We will prioritise research that guides the development of our own supports and informs our advocacy to improve public services for people dying from cancer.





# REPORT OF THE BOARD



# STRATEGIC REVIEW

At the Irish Cancer Society, we are working to a vision that by 2025, three out of four Irish cancer patients will survive their diagnosis and everyone affected by the disease will have access to world-class treatment, care and support. In future, no one in Ireland will die from cancer.

As a community we strive to achieve this vision through our strategic priorities:

**Healthy living:**  
Fewer preventable cancers

**Catching cancer early:**  
More cancers caught early

**Treating cancer:**  
World-class cancer treatment for everyone

**Living well:**  
Living well after treatment

**End-of-life care:**  
Holistic support for people dying from cancer

Progress will be made across all our priorities through our three pillars of activity: advocacy, services and research. This work is enabled by our fundraising efforts and having the right people, processes and technology in place to support our progress and performance.

## Strategic context

Although COVID-19 remains a concern, 2022 saw Ireland shift from pandemic to post-pandemic as many restrictions lifted and society returned to its new normal. This impacted all areas of the organisation. We supported patients as they adjusted to the fear and worry about reopening and as they felt, at times, left behind. Our shops reopened and we had our first year of full trading since 2019. We transitioned to a new hybrid working model for previously office based staff. As political and media attention moved on, we also maintained focus and attention on the long-lasting legacy of COVID-19 for cancer patients.

Throughout the pandemic we continually drew attention to the delayed diagnosis of cancer, and missed cancer diagnoses. In 2022 we maintained this call and expanded our efforts, such as our early detection roadshows. Addressing this delay and re-focusing on early detection will continue to be a major priority for the Society into 2023 and beyond.

2022 also saw unexpected and unpredicted challenges. Russia's invasion of Ukraine led to many Ukrainians being forced to leave their homes and seek refuge, with

about 70,000 coming to Ireland. For Ukrainians with cancer, this meant leaving their clinical care and their support network, to navigate a new health system in a foreign country through a foreign language. We were proud to immediately respond, translating cancer information into Ukrainian, and hiring a Ukrainian cancer coordinator who worked with patients and families who had come to Ireland, bridging the gap before the HSE established such roles. In 2022 we also saw inflation rise and the cost of living increase. For cancer patients, who often have reduced income and increased expenses as a result of their diagnosis, the cost of living crisis takes a huge additional toll. This pressure has increased the urgency and importance of our practical and financial supports and services, and the need to advocate to reduce the financial burden on patients. This need will continue into 2023 and will remain a focus for us.

The cost of living crisis also impacts the Irish Cancer Society just like any organisation. We have seen energy bills and operating expenses rise, and it is costing the Society more to deliver the same services and reach. Despite this we have still managed to increase the work that we do and the impact that we make for people affected by cancer. We continue to





Progress will be made across all our priorities through our three pillars of activity: advocacy, services and research.



Director of Services, Corinne Hasson, and CEO, Averil Power, at the Living Well With and Beyond Cancer conference in September 2022.

be blown away by the generosity of supporters, who despite also feeling the pressures of the cost of living crisis continue to fund our important work.

Into 2023, we will continue to manage our costs, grow our work where we can, and deliver and communicate impact, so that our supporters can continue to see the difference that their money makes for people affected by cancer.

The beginning of 2023 marks the mid-point of our 2020-2025 strategy. A lot has changed since the strategy was developed, but the core tenets of it remain relevant. In 2023, we will conduct a mid-point review of our strategy and adapt as needed. We will continue to retain our focus on ensuring that we reach and support

more people affected by cancer, and work to bring forward the day when everyone lives – and lives well – after a cancer diagnosis.

### Achieving our 2022 goals

In our annual report 2021, we set 52 new objectives for 2022. Of these, we achieved 29 (56%), 16 (31%) were achieved in part or remain in progress, and five (10%) were not achieved. Two objectives set were postponed during 2022, as we decided not to proceed with them in response to the changing context.

Progress made against each of our 2022 objectives is detailed in the following sections of this report, under each of the strategic priorities and enablers.

**Objectives achieved:** Where goals are achieved in 2022, we will continue to work to build on this work into 2023 and beyond, until we can reach the day that no one dies from cancer and everyone has access to world-class treatment, care and support.

**Objectives achieved in part/ in progress:** Where objectives were achieved in part rather than in full, or remain in progress, this was typically where they are ongoing goals that we will continue to work on into 2023 and beyond.

**Objectives not achieved/ postponed:** This was typically where we made a choice to reprioritise and refocus our resources and energy toward new or more urgent challenges.



# Healthy living

## Our goal

We are working for a future with fewer preventable cancers.

## To achieve this

we will influence Government policy and laws so that everyone has the best chance of living a life free from cancer.

we will invest in research that uncovers new ways to prevent cancer.

we will provide advice to those who need it.

## The impact we had in 2022

The health of our planet has a direct impact on the health of the people who live on it. In 2022 we jointly funded research with the Irish Heart Foundation, to be conducted by the ESRI, on climate related health impacts. We will share its findings in 2023. We are also proud to be a part of the Climate Health Alliance (CHA), an alliance of charities, academics and professional bodies, advocating for Government action on climate change and its impact on public health. With the CHA, we have advocated for active travel and against air pollution, making submissions to influence the national clean air strategy and local active travel strategies.

Skin cancer remains the most common cancer in Ireland, with outdoor workers particularly at risk. Our skin cancer campaign ran in May, to increase awareness of signs and symptoms of skin cancer. We also continued to work with Healthy Ireland and the National Cancer Control Programme (NCCCP) to implement the National Skin Cancer Prevention Plan and deliver the SunSmart campaign.

We're always looking at ways to make the healthy choice the easy choice, so in 2022 we piloted sunscreen dispensers. These dispensers included SPF 30 sunscreen, along with information on the UV index and the SunSmart code. The dispensers were piloted with employers such as An Post and Dublin Airport Authority, with Water Safety Ireland, and with community organisations and at events across the summer.

The human papilloma virus (HPV) vaccine, protects against the types of HPV that cause nine out of ten cervical cancers. The vaccination programme paused during COVID-19 and recommenced in 2021 but needed a catch-up programme, to ensure that school children who missed out on their scheduled vaccine were able to receive it. Along with the family of the late Laura Brennan and other campaigners, we campaigned for this programme and welcomed the launch of the Laura Brennan HPV Vaccine Catch-up Programme toward the end of the year.

As part of our work toward a Tobacco Free Ireland, we also continued to advocate for Government regulation of electronic cigarettes to tackle the inappropriate targeting of young people. In 2022, the Joint Committee on Health completed their pre-legislative scrutiny of the Public Health (Tobacco and Nicotine Inhaling Products) Bill. We were pleased to see the report included recommendations, which we have advocated for, to regulate the flavouring and marketing of e-cigarettes to young people but disappointed not to see such areas reflected in full in Government's proposed Bill. We will continue to push for the legislation to go further, in particular to regulate flavours that entice young people to vape.

45

Days the Your Health Matters Roadshow was operational

↑ Up from 21 days in 2021

9 out of 10

The human papilloma virus (HPV) vaccine, protects against the types of HPV that cause 9 out of 10 cervical cancers.



# Achieving our objectives

2022		
Objective	Results	Progress
<b>Continue to campaign for the full implementation of the Public Health (Alcohol) Act.</b>	Provisions on alcohol advertising and minimum unit pricing came into effect in January 2022. Alcohol warnings have been approved by the European Commission, but have not yet been signed into law.	In progress
<b>Push Government to go further on proposed e-cigarettes legislation, to tackle the inappropriate targeting of young people by e-cigarette advertising and flavours.</b>	Government has agreed to further regulate e-cigarettes, including limiting advertising, but has not included a ban on flavours.	In progress
<b>Press for a blanket catch-up for the HPV vaccination programme in schools, after COVID-19 disrupted roll-out, to ensure children are protected from HPV-related cancers.</b>	The Laura Brennan HPV Vaccine Catch-up Programme launched in November 2022.	Achieved
<b>Work with the HPV Alliance to push for accelerated progress on the elimination of HPV-caused cancers.</b>	Continue to work toward this goal including as a member of the HSE's Cervical Cancer Elimination Group.	In progress
<b>Continue our pilot project to address the needs of patients with a genetic or high familial risk of cancer.</b>	This project recommenced (after a pause for COVID-19) in January 2022.	Achieved Goals for 2022 achieved, with further progress targeted in 2023
<b>Work with the Climate and Health Alliance (CHA) to highlight the public health harms of climate change, and advocate for Government action.</b>	Advocated with the CHA in particular in the areas of active travel and air pollution.	Achieved Goals for 2022 achieved, but this remains an ongoing objective
<b>Support the implementation of the National Skin Cancer Prevention Action plan.</b>	Continued to work with stakeholders on actions across the Action Plan.	Achieved Goals for 2022 achieved, but this remains an ongoing objective
<b>Develop a longer term cancer prevention, awareness and early detection strategy for the Society.</b>	Postponed for 2022, as we focused on urgent early detection needs.	Not achieved To be developed in 2023



Carol, Sharon, Saoirse and Niamh at the Women's Mini Marathon.



## Our objectives for 2023

- » Develop an organisation wide Prevention and Early Detection Plan for 2023-2025.
- » Advocate for Government to put more supports in place to make it easier for people to quit smoking.
- » Advocate for health warnings on alcohol products.
- » Continue to push for a ban on flavoured vaping products.
- » Educate people about how to prevent cancer through community-level talks.



# PAUL



Sometimes we can take a bit of a macho attitude and pretend there's nothing wrong, but if you notice anything strange then you should listen to what your body is telling you.





## I've always tried to stay fit and active in my life. I ran in three marathons when I was younger, and just a few years ago I walked 120km along the famous Camino di Santiago.

In 2020 during the lockdowns I was diagnosed with a form of cancer called Non-Hodgkin's Follicular Lymphoma. This affected my spleen, spine and gullet.

I always thought these things apply to other people, but not to me. Those other people could get cancer, but I won't get sick. But the truth is it can happen to anyone.

Staying healthy and active is very important when it comes to lowering your cancer risk, but it's also helpful for giving yourself the best chance possible through treatment and recovery.

I felt incredibly lucky as the doctor told me my cancer was treatable and indeed curable. My side effects from the chemo were also manageable, besides nausea and the hair loss.

In April 2021 I was delighted to get the news that I was cancer-free. In terms of staying active, I had been doing the

volunteer driving for the Irish Cancer Society even before my own diagnosis. I had to pause it for a while during treatment, but I was happy to be able to go back to it afterwards.

Whereas my marathon running days may be behind me, I still enjoy going out golfing every week.

One thing I am very strong on now is for men in particular to get themselves checked for any problems they're having.

Sometimes we can take a bit of a macho attitude and pretend there's nothing wrong, but if you notice anything strange then you should listen to what your body is telling you. Catching cancer early can be a big help when it comes to increasing your chances of surviving and thriving, like I have.

**Paul,  
Survivor and volunteer**

# 3,000

people volunteered in 2022

↑ Up 20% from 2021



# Catching cancer early

## **Our goal**

We are working for a future where more cancers are caught early.

## **To achieve this**

We will lead advocacy campaigns, innovate services, fund research, and work in partnerships that will eliminate the survival gap between Ireland and other European countries.

We will give people the best chance of surviving cancer.

## The impact we had in 2022

2022 saw the lifting of COVID-19 pandemic restrictions, but the legacy of delayed diagnosis of cancer continued to be a huge concern. We prioritised our work under the “Catching cancer early” priority to help address this crisis.

Our Your Health Matters Roadshow, piloted in 2021, aims to raise awareness of cancer signs and symptoms and encourage and enable people to access healthcare. Independent evaluation of the pilot found that the pilot was successful in achieving these goals, and this led to us expanding the programme in 2022.

In 2022 the Roadshow went nationwide, visiting 20 locations over 46 days. The Roadshows visited shopping centres and events like the Ploughing Championships, offering people information about cancer signs and symptoms and a free, nurse-led health check. Staff and volunteers engaged with over 18,000 people at the Roadshows, and nurses conducted almost 1,700 health checks. As a nurse led service, and operating according to the Society’s values, the Roadshow provides a way to engage with people in a compassionate, open and non-judgemental way.

A key strategic goal for us is to reduce health inequalities and inequality of outcomes. In 2022, we launched a partnership with the Capuchin Day Centre and Safety Net Primary Care to support users of the Centre’s food aid service, who may be homeless or otherwise marginalised. Through this partnership, Irish Cancer Society nurses were available in the Capuchin Day Centre to carry out health checks, discuss signs and symptoms of cancer, and refer people to additional health services they may need. Nurses conducted 156 health checks through the partnership from its launch in July to the end of 2022, and the partnership will continue into 2023.

Throughout the year we also continued awareness campaigns targeting common cancers, and cancers which are more likely to be caught later. Our Lung Cancer Awareness campaign in January had a media reach of 5.1 million, with 10,000 views of our lung cancer information pages and more than 1,200 people taking our lung health checker quiz. April saw our Bowel Cancer Awareness campaign, which highlighted our research that one in two people were not confident in spotting the signs of bowel cancer, and also advocated for action on waiting times for colonoscopies. The campaign saw almost 22,000 page views within our bowel cancer information section of cancer.ie, a doubling of the views from the 2021 campaign.

Throughout all our awareness campaigns we also trialled and tested new ways to engage and connect with people. This included bathroom advertising for bowel and prostate cancer awareness, Instagram Q&As with our cancer nurses, and working with community groups such as Men’s Sheds.

Our “Care for Your Pair” Breast Cancer Awareness campaign in October had a high level of engagement, increasing awareness of breast health and early detection. We worked with partners to connect with more people. This included partnering with Primark in their collection in honour of the late Sarah Harding, working across social media platforms, and sharing the stories of women and men who have been affected by breast cancer. The campaign had a media reach of 5.2 million, as people across the country “cared for their pair”.

Our Daffodil Centre nurses around the country also worked to promote our cancer awareness messages and campaigns among hospital staff, patients and visitors. They spoke to

**“ Usually people might be judgemental, so it is great to be able to have an open discussion about cancer.**

**Roadshow attendee**

7,500 people at awareness sessions throughout the year, supporting cancer awareness days and months, as well as raising general awareness of cancer signs and symptoms, and promoting cancer screening services.

Cancer screening is a key tool in catching cancer early. Through 2022 we continued to advocate for improvements to cancer screening in Ireland, recommending to the National Screening Advisory Committee ways to enhance existing programmes and take-up, and campaigning for new national lung cancer and prostate cancer screening programmes.

We also funded research in 2022 to increase knowledge of how to catch cancer early. Findings published by researchers supported by the Society show the impact of some of that work. Dr Emma Allot, recipient of the Irish Cancer Society John Fitzpatrick Fellowship, published a review of the causes of prostate inflammation and its relationship to prostate cancer, in particular aggressive prostate cancer and an analysis between statins and prostate cancer. Dr Allot’s work, and its emerging insights can provide hints for the development of treatment and prevention strategies for advanced prostate cancer, helping to catch and treat cancer early.



# Achieving our objectives

2022		
Objective	Results	Progress
<b>Work with the National Cancer Screening Service to increase uptake of screening, in particular implementing the outcomes of our funded research into Bowel Screen uptake.</b>	<p>We continued to campaign for the widening of the age brackets for screening, new programmes and the full return of screening programmes post-COVID.</p> <p>Through our Roadshow we raise awareness of screening and encourage take-up.</p>	In progress
<b>Expand the Your Health Matters early detection roadshow and double the number of people we provide advice, information and support to.</b>	The Your Health Matters Roadshow ran for 46 days in 2022, more than double the 21 days of operation in 2021.	Achieved
<b>Implement early detection initiatives for particularly at-risk and marginalised groups.</b>	Our partnership with Capuchin Day Centre and Safety Net Primary Care launched in July 2022.	Achieved
<b>Continue to track and monitor the ongoing impact of COVID-19 on health attendance, cancer detection and diagnostics, and take action to mitigate these effects.</b>	Ongoing monitoring throughout 2022, with survey results and findings incorporated into our awareness campaigns and advocacy.	Achieved
<b>Develop cancer awareness information and tools for employers, universities and schools.</b>	Cancer awareness talks and information sessions were held across a wide range of workplaces and community groups. Further work is planned to expand this offering in 2023.	Achieved in part
<b>Raise awareness of cancer signs and symptoms, and drive a 20% increase in visits to relevant information on cancer.ie during key cancer awareness months and days.</b>	Awareness campaigns ran across all key cancer awareness months, with the 20% target increase exceeded for key months e.g. doubling of bowel cancer page views compared to 2021 bowel cancer awareness month.	Achieved
<b>Lobby for the content of the Irish Cancer Society submissions to the National Screening Advisory Committee to become Government policy.</b>	Continued to advocate to the National Screening Advisory Committee and to the National Screening Service.	In progress



The Irish Cancer Society Your Health Matters Roadshow at the Jervis Centre.




## Our objectives for 2023

- » Increase the reach of the Roadshows, and operate for at least 60 days in 2023.
- » Develop and implement an expanded workplace awareness and early detection awareness programme.
- » Recruit and train cancer awareness volunteers within communities to support awareness activities and campaigns.
- » Continue to deliver integrated cancer awareness public campaigns, and increase the people reached through this work.
- » Evaluate the Capuchin Centre partnership, and use these learnings to continue to expand this service.
- » Identify opportunities for further partnerships to reach and support at risk-groups.
- » Fund world-class cancer research programmes and pilots specifically focused on improving the early detection rates of cancer.

Catching cancer early

# TOM





## I began volunteering with the Irish Cancer Society a few years ago. I had retired and was looking for something to do.

I was at the doctor's one day for a check-up and he told me: "Tom, I don't see you sitting around doing nothing". He mentioned to me volunteer driving for the Irish Cancer Society. So I read up about it, did the course and that was that.

I do a drive every week on a Tuesday now, taking patients from places like Finglas, Tallaght and Celbridge into treatment and collecting them when they're finished.

A couple of years after starting the driving I was asked about volunteering at the Irish Cancer Society's Your Health Matters Roadshow.

It was one of their first roadshow events, which aimed to inform people about the signs and symptoms of cancer, and encourage them to see their doctor over any concerns or worries they might

have. There were nurses present all day offering free tests including for body mass index (BMI) and carbon monoxide readings as well as giving advice on cancer prevention, screening, and signs and symptoms.

It was an opportunity to give something a bit different. I really enjoyed chatting to the people who stopped by and being able to help get people the information they needed on cancer prevention and detection.

Overall I'm conscious that I've been very lucky in my life, between family, business and everything. Whether you call it religious or just karma I've always just wanted to give something back: that's what I'm all about.

**Tom,  
Volunteer**



The roadshow events inform people about the signs and symptoms of cancer, and encourage them to see their doctor over any concerns or worries they might have.



# Treating cancer

## **Our goal**

We are working for a future with world-class cancer treatment for everyone.

## **To achieve this**

We will lobby Government so that all cancer patients are given timely access to treatments that will work best for them.

We will reduce the fear of cancer through our support services and invest in research that has the potential to transform lives.

# The impact we had in 2022

Cancer research can bring forward the day where everyone lives, and lives well, after a cancer diagnosis. In 2022, the Irish Cancer Society remained the largest voluntary funder of cancer research in Ireland, investing €3.7 million in cancer research including cancer trials. 60% of this funding went toward research to support our “Treating cancer” goal: new Irish research to advance world-class treatment for everyone.

Irish Cancer Society funded researchers made breakthroughs and advances to improve how patients are treated. This included PhD Scholar Romana Silva, who conducted research into ovarian cancer. Her research led to the development of a new type of blood testing which can detect a specific type of mutation associated with this cancer. In future, this test could potentially provide a non-invasive way to monitor ovarian cancer patients through their treatment.

Our research funding also supports leading treatments and therapies being brought to Ireland. Our support of Prof Janusz Krawczyk through our Clinical Trial Catalyst Award means that Irish lymphoma patients will have access to cutting-edge CAR-T immunotherapy treatment.

Supported by our €1 million investment in Cancer Trials Ireland, over 1,000 new patients joined a CTI supported cancer trial in 2022 (a 15% increase on 2021). We will continue our partnership with CTI,

to increase access by Irish patients to potentially life-saving and life-changing treatments.

When a patient, or their loved one, is undergoing treatment it can feel like there’s a million questions. Our Freephone Support Line and Daffodil Centre nurses are there to listen, support and give reliable, trustworthy information. In 2022, there were over 21,500 calls, emails and conversations across our Support Line and Daffodil Centres. As all our Daffodil Centres reopened, and hospitals became more accessible, we saw over 13,000 support conversations in Daffodil Centres, a 49% increase on 2021. With Daffodil Centres open again, and people able to avail of face-to-face support, our Support Line saw a slight decline in calls and contacts, down to just over 8,000 (-6% on 2021).

We further increased the tailored supports for children, teenagers and their families, affected by a childhood cancer diagnosis. We published two new children’s cancer booklets, including one on supporting siblings of a child with cancer, providing parents and families with reliable and practical advice. In conjunction with Relay for Life Donegal, we also developed a resource for teachers to support them to talk to children in their classrooms about cancer. We partnered with Children’s Hospital Ireland (CHI) Crumlin, the specialist national centre for childhood cancer, to increase the supports offered to families. Our Childhood Cancer

Coordinator now attends at CHI Crumlin one day per week to provide advice and support to children and their families, as they are going through this devastating diagnosis. We also extended our volunteer driving services to bring children and their parents to treatment in CHI Crumlin, free of charge. The service now covers over 40% of attendees to CHI Crumlin, covering families in Dublin, Kildare, Meath and Wicklow. It is our plan to extend this even further in 2023.

Our adult volunteer driving service saw a significant increase in demand in 2022. The service provides for a volunteer to collect a patient from their home and drive them to and from their chemotherapy treatment in 31 partner hospitals nationwide. The services is open to all, and completely free-of-charge for the patient. In 2022, almost 1,800 patients were driven to and from almost 17,000 appointments. This is an increase of 30% on the number of drives completed in 2021. We also piloted expanding the service to radiotherapy patients, trialling this in the Cork area in the second half of the year. This expansion, and meeting the increased demand generally, is only possible thanks to the volunteers across the country who give their time to this vital service. Almost 1,000 drivers volunteered over the course of 2022, and we are immensely grateful to them. Thanks to their efforts, 99.9% of requests for drives were delivered.

# 1,800

patients driven to and from cancer treatment in 2022

↑ Up 31% from 2021





# Achieving our objectives

2022		
Objective	Results	Progress
<b>Expand our pre-treatment workshops for patients to provide information, advice and support to every patient undergoing treatment for cancer.</b>	Three new pre-treatment workshops were developed in 2023, to add to the existing pre-chemotherapy workshop. Roll-out of these modules will take place in 2023.	Achieved in part  Roll-out of these modules will take place in 2023.
<b>Increase by 10% the number of patients we support through our volunteer driving service.</b>	2022 saw a 31% increase in the number of patients supported through our volunteer driving service.	Achieved
<b>Conduct a pilot to serve patients travelling to radiotherapy appointments through our volunteer driver service.</b>	A pilot commenced in the Cork area to bring patients to radiotherapy appointments. This pilot service will continue into 2023, and we will look at ways to expand it while continuing to meet the demand nationwide.	Achieved
<b>Open the volunteer driving service to children and teenagers travelling to CHI Crumlin.</b>	This service opened for patients in Dublin, Kildare, Meath and Wicklow, covering over 40% of families visiting CHI Crumlin.	Achieved
<b>Increase the number of people supported by our SupportLine by 10%.</b>	Our Support Line saw a slight decline in calls and contacts, down to just over 8,000 (-6% on 2021), but this was negated by the increase in Daffodil Centre contacts as 2022 saw an increase overall in our contacts with nurses.	Not achieved
<b>Continue to restore our Daffodil Centres to pre-pandemic attendance, on-board new volunteers and increase the number of people supported through our Daffodil Centres by 20%.</b>	We saw over 13,000 support conversations in Daffodil Centres, a 49% increase on 2021.	Achieved
<b>Increase the number of patients on cancer trials funded by the Society through our investment in Cancer Trials Ireland.</b>	Over 1,000 new patients joined a CTI supported cancer trial in 2022, a 15% increase on 2021.	Achieved
<b>Invest €700,000 in new translational research.</b>	Over the course of the year, we invested over €800,000 in translational cancer research	Achieved



2022		
Objective	Results	Progress
<b>Offer a tailored information pack to every newly diagnosed person who contacts the Society, providing relevant information and resources to support their diagnosis.</b>	While work on designing and developing this commenced, this objective was not achieved in 2022.	Not achieved. This will be rolled-out in 2023.
<b>Provide additional advice, information and support to families affected by childhood cancer.</b>	We increased the advice, information and support offered to families through our Children's Cancer Coordinator service in CHI Crumlin, new information booklets and increased awareness activities.	Achieved
<b>Advocate for continued increases in funding for cancer services and delivery of infrastructure and change to support implementation of the National Cancer Strategy.</b>	An additional €20 million was allocated for the implementation of the National Cancer Strategy and cancer services in Budget 2023	Achieved Goals achieved for 2022, but we will continually advocate for the roll-out of the National Cancer Strategy and funding for cancer services

## Our objectives for 2023

- » Roll-out three new pre-treatment workshops for patients to provide information, advice and support to every patient undergoing treatment for cancer.
- » Increase by 20% the number of patients we support through our volunteer driving service.
- » Complete and evaluate the Cork pilot for patients travelling to radiotherapy appointments through our volunteer driver service.
- » Increase the areas covered by the volunteer driving service for children and teenagers travelling to CHI Crumlin.
- » Increase the number of support conversations conducted by our nurses on the SupportLine and in Daffodil Centres by 10%.
- » Increase the number of patients on cancer trials funded by the Society through our investment in Cancer Trials Ireland.
- » Invest over €1 million in research funding to support our Treating Cancer goal.
- » Provide additional advice, information and support to families affected by childhood cancer.
- » Advocate for continued increases in funding for cancer services.
- » Invest in strategic partnerships to advance world-class cancer treatment for everyone

# JARUSHKA



Immunotherapy is our sort of poster child for hope; it's a new type of treatment that uses the body's immune system to fight cancer, and can help many different cancer types.



My research focuses on two main areas: on lung cancer and immunotherapy.

Lung cancer we know is a very serious diagnosis; it's the most common cancer of men and women that leads to cancer-related deaths.

Immunotherapy is our sort of poster child for hope; it's a new type of treatment that uses the body's immune system to fight cancer, and can help many different cancer types.

Research is here to serve the patients, and to ask questions that are relevant that will help patients to either live longer or live better.

Oncology and cancer research is constantly evolving so that what we do today is going to be nothing like what we do in 10 years, and I find that extremely exciting to be able to be a part of that.

In 2022 I received the Irish Cancer Society's Clinician Research Leadership Award, which allows me time to focus on forward-looking cancer research projects away from my day-to-day clinical hospital duties. Through this transformative award I am focussing on three main projects.

The first is an investigator-initiated clinical trial called the ADEPPT Trial that is bringing a new targeted therapy to patients with lung cancer.

The second is to bring together a group of specialists focused on the toxicities of immunotherapy to try to understand how patients' lives are affected by immunotherapy, and improve their quality of life.

The third project is to bring together clinical and basic science researchers who are interested in lung cancer in a new group called the Irish Lung Cancer Alliance, in order to develop innovative new clinical trials and projects.

It's incredibly rewarding to be part of this dynamic environment bringing new treatments to patients.

**Jarushka,**  
Cancer researcher

139

cancer researchers funded by the Society in 2022

↑ Up 3% on 2021

1,000

new patients participating in cancer trials with Cancer Trials Ireland

↑ Up 15% from 2021



# Living well

## **Our goal**

We are working for a future where everyone affected by cancer lives well after treatment.

## **To achieve this**

We will make sure the emotional, physical, financial and practical needs of those who have undergone cancer treatment are met.

We will provide services that will directly support people, so they are better able to cope with the impact of cancer.

We will undertake research that will help us improve cancer patients' quality of life.

## The impact we had in 2022

2022 saw the start of the cost of living crisis, which has affected everyone across Ireland. Cancer already has a huge practical and financial impact, and the cost of living crisis adds to these difficulties. At the Irish Cancer Society, we worked to provide direct services and to advocate for national changes to relieve this burden.

In 2022 we launched a new Practical Support and Financial Solutions service. Trained specialists were able to work hand-in-hand with patients and families to help them to manage worries and challenges. The service started with just one advisor but due to demand, we increased to three advisors by end of the year. Over this time, almost 250 patients and families have been supported with advice and practical support on issues such as accessing benefits and entitlements, landlord and tenancy issues, arranging childcare, and workplace supports.

These are the same issues that we have been tirelessly advocating to resolve at a national level also. We continue to produce and update our Real Cost of Cancer research, spotlighting the financial burden of a cancer diagnosis. After years of campaigning, and following our pre-budget submission, we welcomed the Budget 2023 announcement that hospital in-patient charges will be abolished. This is a huge relief for patients who are already struggling to make ends meet. Into 2023, and beyond, we will continue to campaign for further measures such as reducing hospital car-parking charges and providing every cancer patient with a medical card.

2022 also saw our “Leave our Leave” campaign to allow women defer maternity leave following a cancer diagnosis. Cancer survivors Erica Tierney, Mary Canavan and Emma McGuinness championed the campaign to address this legislative anomaly. Erica received a breast cancer diagnosis while 30 weeks pregnant and, in her words: “my maternity leave ended the week after I finished treatment. I was really sick from treatment, totally bald and

hardly able to shuffle to the shop let alone go back to work. Yet that was my maternity leave gone.” The campaign received much media attention, and we are hopeful for legislative change in 2023.

In 2021, the Society worked with the ESRI to research the experience of people affected by cancer returning to work after their diagnosis or treatment. In 2022, we worked to support the implementation of the recommendations arising from that research. As part of Breast Cancer Awareness Month in October, we launched employer guidelines to support employees with breast cancer along with further online resources and information. We also engaged throughout the year with employers, trade unions and other stakeholders, to support the implementation of these guidelines.

The impact of a cancer diagnosis can persist long after treatment ends. In February 2022 we published a report on “the right to be forgotten”, highlighting how, years after a cancer diagnosis, survivors are experiencing difficulties accessing financial products. Many people, particularly people diagnosed with cancer as children or adolescents, face unjust financial penalties years or decades after their treatment has ended, being unable to access loans or insurance.

Following our campaigning, the Oireachtas Cross Party Group on Cancer brought forward the Central Bank (Amendment) Act 2022. The Bill provides that a person seeking access to financial services will no longer have to declare a cancer diagnosis five years after finishing active treatment. With cross-party support, the Bill was introduced in the Seanad in November 2022 but did not pass second stage. In 2023, we will continue to campaign for its progress.

Cancer also takes an emotional and psychological toll. The Irish Cancer Society provides free counselling services to people affected by cancer, at every stage of their journey. In 2022, we supported over 16,000

**I would like to take this opportunity to appreciate the Irish Cancer Society, especially Louise, Patrick and Itunu for helping me to advocate my housing issue together. I strongly believe, without your generosity, time and effort, my housing predicament [would not have been resolved] so smoothly.**

**User of the Practical Support and Financial Solutions service**

counselling sessions for over 3,200 people, through our network of remote counsellors and through the counselling services we fund in community cancer support centres nationwide. This represents a 16% increase in the number of people supported through these services, as compared with 2021.

We also extended the types of survivorship supports offered, recognising that the ongoing effects of cancer can be wide ranging. Survivors can now access coaching services, oncology dietitian services, and specialist exercise programmes through our expanded survivorship supports pilots.

For children and their families, and for young adults, cancer takes so much. In 2022 we partnered with Barretstown to run special camps for children with cancer and their families, and for young adults affected by cancer. These camps provide an escape away from the challenges of cancer and treatment, allowing children and young people to be themselves. The camps also provide a vital connection to supports and services, and to connect with others experiencing the same challenges. Over 2022 we supported six camps, attended by 52 families and 35 young people.



We continued to fund new cancer research in the area of survivorship, launching our Men’s Health Initiative. The Irish Cancer Society Liam Mc Trial (short for Linking In with Advice and supports for Men with Metastatic Cancer) is a 12-week programme of wrap-around supports to meet the emotional, practical and physical needs of men affected by cancer. The initial phase of the Liam Mc Trial focuses on men with genitourinary cancer, but the aim of the research is to develop a programme to help all men to live full and fulfilling lives during and after cancer treatment.

The Liam Mc Trial is the “brother” to the Women’s Health Initiative, a research programme developing survivorship supports for women

affected by cancer. In 2022 we increased our funding for the WHI, enabling the WHI Centres in Cork and Dublin to extend their programmes for a further two years and extending the initiative to Galway University Hospital so that more patients can benefit from its work.

We also launched a three year pilot project taking place in University Hospital Limerick focusing on the early detection of cancer-related lymphoedema. Lymphoedema can be a side-effect of cancer treatment. If detected early, lymphoedema can be kept under control and its impact on day-to-day life managed.

We further funded researchers from all disciplines to advance survivorship research. Over the course of 2022, we provided €1.2 million in funding for survivorship research and researchers.

**“Cancer survivorship is on the rise and I still have a full life to live, so it’s not good enough that people such as myself will continue to be denied fair access for something so important.”**

**Cancer survivor Sam Russell, speaking about the “right to be forgotten”**

## Achieving our objectives

2022		
Objective	Results	Progress
<b>Conduct a national patient experience survey to more fully understand the experience of people living after cancer and use these insights to develop new services and campaign for change</b>	As the NCCP intend to conduct a national patient survey, the Society has held roll-out of its own national survey pending this. We have continued to conduct smaller surveys on specific topics to support our advocacy efforts and understanding.	Postponed
<b>Launch a Men’s Health Initiative, modelled on the Women’s Health Initiative, to ensure access to world-class care for all survivors of cancer.</b>	We launched the Liam Mc Trial, to develop a programme of world-class holistic support for survivors of cancer.	Achieved
<b>Further grow our financial and benefits advice services and provide individual advice to people who need it.</b>	Introduced a personal one-to-one financial and practical advice service, serving almost 250 patients and families in 2023.	Achieved
<b>More than double participation in our Life and Cancer – Enhancing Survivorship (LACES) survivorship programme</b>	We saw a 60% increase in the number of participants, but the doubling (100% increase) target was not met.	Achieved in part
<b>Host a hybrid (online and in-person) survivorship conference, and grow attendance by more than 30% over 2021.</b>	We held our Living Well conference in September as a hybrid event. Attendance numbers were 10% down on 2021 however, and in 2023 we will reconsider our approach to events to reflect post-COVID changes in how people want to engage.	Achieved in part

2022		
Objective	Results	Progress
<b>Develop and fund a world-class survivorship research coalition to improve outcomes for people affected by cancer.</b>	In light of new opportunities and challenges arising, we decided to support cancer survivors through our direct services and individual research grants, and not progress with a large-scale research coalition.	Postponed
<b>Invest €1.9 million into new survivorship research.</b>	In 2022, we invested over €1.2 million to fund world class cancer survivorship research. Gap in target is due to the above decision regarding the survivorship research coalition.	Achieved in part
<b>Advocate and campaign to reduce the financial impact of cancer for patients and families, particularly in light of the rising cost of living.</b>	We advocated across a wide range of areas (see above) and particularly welcomed the abolition of hospital in-patient charges and progress on legislation allowing for the “right to be forgotten”	Achieved
<b>Publish research on the challenges cancer survivors face in accessing financial services post-treatment and support practical steps, such as the “right to be forgotten”, to improve access to financial services.</b>	“Right to be forgotten” report published in February 2022. Alongside the Oireachtas Cross Party Group on Cancer we also drafted, published and brought to Second Stage the Central Bank (Amendment) Bill to improve access to financial services.	Achieved
<b>Provide over 13,000 sessions of counselling through our remote counsellors and through partnership with cancer support centres.</b>	Over 16,000 counselling sessions provided in 2022	Achieved
<b>Pilot new community based supports for people affected by cancer.</b>	Coaching services, oncology dietitian services, and specialist exercise programmes are being piloted.	Achieved.

## Our objectives for 2023

- » Open an Irish Cancer Society community service to provide survivorship supports to people in areas that are currently underserved.
- » Increase the number of people benefiting from the Society’s survivorship supports and patient education programmes.
- » Increase awareness of our Practical and Financial Advice services and increase the number of people supported.
- » Complete a pilot of a holistic needs assessment, to provide a means for people to access the full range of supports and services that they need.
- » Pilot new survivorship supports for children, adolescents and young adults (CAYA).
- » Increase the range of supports provided for CAYA through new funded posts and staffing.
- » Run six camps for families and young people in partnership with Barretstown.
- » Continue to advocate for changes to reduce the practical and financial burden of cancer, building on past work.

# DONNA-MARIE



Fortunately, cancer is no longer controlling my time. Thanks to the fantastic medical and emotional services out there, I can plan my own time again now.





## In 2020 I was diagnosed with Ewing Sarcoma – a rare, complicated and aggressive cancer. I had just given birth to Max, our second child, when I discovered a lump on my head beside my right eye.

As you can imagine, at 35 years of age with a young family I didn't expect to be dealing with a life-threatening cancer diagnosis. No one does.

Chemotherapy was overwhelming and exhausting. COVID-19 meant I had to go through treatment in isolation. Sometimes I couldn't hold back the tears.

But it was so reassuring to know that an Irish Cancer Society nurse was at the end of the phone to answer a worry or just to give me some company – to let me have a cry, or even help me have a laugh.

They took the loneliness out of being alone. They reminded me every time I spoke to them that it was okay to have those dark times, because those emotions were only there to visit, not to stay.

When I think back on all the time that cancer took away, I realise it's the everyday

experiences of life that I missed the most. Time just being Mam to my kids.

The amazing services of the Irish Cancer Society – the counselling, the chats, the tireless support, the enlightening information that is all free of charge – helped the time spent with my family feel even more precious.

More importantly, they helped us fill our time with joy, connection and generosity. It gave me confidence and knowledge, a solid foundation of support, and the wonderful sense of being cared for.

Fortunately, cancer is no longer controlling my time. Thanks to the fantastic medical and emotional services out there, I can plan my own time again now.

**Donna-Marie,  
Survivor and advocate**

# 13,350

Support conversations with our Daffodil Centre nurses

↑ Up 49% from 2021

# 3,250

people supported by remote and in-person counselling

↑ Up 16% from 2021



# End-of-life Care

## Our goal

We are working for a future where there is holistic support for people dying from cancer.

## To achieve this

We will ensure people dying from cancer have access to the full range of supports needed by them and their families.

We will drive changes from Government that will mean more people can die at home.

We will prioritise research that guides the development of our own supports and informs our advocacy to improve public services for people dying from cancer.

# The impact we had in 2022

Throughout 2022, we continued to provide free in-home nursing care to patients at end-of-life. This service allows patients to die at home, surrounded by their families and loved ones.

Over the course of the pandemic, we saw a significant rise in the number of patients wishing to avail of our night nursing service, due to restrictions on visiting and risks with nursing homes, hospices and hospitals. Thankfully, these restrictions eased in 2022. In 2022 our nurses provided care to almost 2,050 patients with cancer, delivering nearly 6,600 nights of care. This represents a drop of 9% in the number of patients supported compared with 2021, as the service returned to pre-pandemic levels. Requests for nights of care for cancer patients in 2022 was broadly similar to that in 2019 (2% higher in 2022 compared to 2019).

We continued to face challenges in securing nurses to deliver the service, as nationally we are facing a

nursing shortage across all areas of healthcare. Over the course of the year, over 200 nurses provided nights of care but despite their best efforts we were unable to provide a night nurse for 13% of nights where one was requested (compared to 12% of requests in 2021).

In addition, we remain concerned that there remains additional need for night nursing and end-of-life care that is not being fulfilled. The service provides up to 10 nights of care for patients, and this can also be extended if needed. We saw that in 2022, patients received on average just over three nights of care. We are concerned that there are barriers for patients in accessing end-of-life care and palliative care in the community, and that patients and families who could benefit from our service are not able to access it early enough.

In 2023, we will conduct research to understand the barriers to accessing night nursing service, to seek to improve our understanding of how

we can support more people to die at home.

We also worked to promote the night nursing service to increase awareness, spotlighting the service as part of our Christmas campaign. We are indebted to the families who have used the service, and the night nurses, who shared their stories throughout December to highlight this important work.

Investing in research to advance palliative care in Ireland also advances our strategy. In 2022 we launched and awarded two specialist Palliative Care Awards. One was awarded to Dr Mary Nevin, in DCU, who will look at how palliative care can be integrated into general oncology practice. Dr Suzanne Delieffe, SETU, was also funded for her work about energy poverty in palliative care at home.

2,050

In 2022 our nurses provided care to almost 2,050 patients with cancer, delivering nearly 6,600 nights of care.

10

The service provides up to 10 nights of care for a patient, and this can also be extended if needed.



# Achieving our objectives

2022		
Objective	Results	Progress
<b>Recruit and retain our dedicated night nursing staff, aiming for 200 night nurses working during 2022.</b>	211 night nurses worked during 2022, and we recruited 43 new night nurses (44 in 2021)	Achieved
<b>Introduce new policies to provide for in-home care for children and young adults at end-of-life.</b>	Continued to advance training and development for our nurses to provide for end-of-life care for children and teenagers.	In progress
<b>Implement further changes to our night nursing processes and technology, so that we can deliver the service more effectively and reach more people.</b>	Some changes implemented in 2022, including moving to a seven days a week administrative and booking services	Achieved Goals for 2022 achieved, with further progress targeted in 2023
<b>Work to ensure the views of patients, carers and family members on assisted dying are considered by Government through a respectful and consultative forum.</b>	Terms of reference have been agreed for a special Oireachtas committee on assisted dying in November 2022.	In progress
<b>Reduce the proportion of nights which we are unable to provide a night nurse from 12% in 2020 to no more than 10%.</b>	Despite efforts to attract and retain night nurses, and the dedication of our night nursing staff, 13% of requests for a night were unable to be fulfilled.	Not achieved
<b>Provide at least 200 more nights of night nursing care to cancer patients.</b>	As the pandemic eased, the demand for our night nursing service decreased and nights delivered returned to pre-pandemic levels.	Not achieved
<b>Advocate for improvements in palliative care provision in Ireland.</b>	We inputted into the new Palliative Care Policy for Adults to improve palliate care provision.	Achieved Goals for 2022 achieved, with further progress targeted in 2023



The Garden of Hope 2022, where daffodils inscribed our supporters' personalised messages are "planted" as a sign of hope, inspiration and remembrance.



## Our objectives for 2023

- » Conduct research about the barriers to accessing our night nursing service, to improve our understanding of how we can support more people to die at home.
- » Recruit and retain our dedicated night nursing staff, aiming for an increase in the number of night nurses working per year and an increase in the average number of nights worked by each night nurse.
- » Reduce the proportion of nights which we are unable to provide a night nurse to no more than 10%.
- » Increase to 6,850 the number of nights of night nursing care delivered to cancer patients.
- » Review the night nursing policies and procedures to ensure and maintain the high quality and governance of the service.



End-of-life care

# BRÍD





## As time goes on I love my job more and more; not just for what I can give, but for what it gives me as well.

---

I had a friend who died in 2015 and I was involved in his care. I had the privilege of meeting one of the Irish Cancer Society night nurses and she gave such wonderful care. It actually inspired me to apply for a job as a night nurse.

Our role is to provide care for a person who is approaching end of life. We also support families and those who have been caring for that person.

The care we provide is not only physical; we also provide psychological care as this can be a very challenging time.

Families and friends caring at home have been getting ready to say goodbye to their loved one, and are often exhausted both physically and emotionally. Their roles can be wide and varied, and sometimes they may not be fully aware of the extent of what they do.

When we arrive it gives families and friends an opportunity to get some rest, safe in the knowledge that their loved one is being looked after and cared for. It also allows them to return to just being a daughter, a son, mother, husband or wife for them.

Families often do tell us how much this intervention meant to them and their loved ones. It is an extremely rewarding job.

To be able to make someone comfortable in those last days is very important. Privilege is a word I use often, and it truly is a privilege to be involved in the care of a person who has chosen to die at home.

**Bríd,  
Night nurse**



When we arrive it gives families and friends an opportunity to get some rest, safe in the knowledge that their loved one is being looked after and cared for.



# Structured for impact

Our strategy requires us to be structured well to effect change and support people affected by cancer. Along with sustainable fundraising, this is the enabler which will help us to achieve our strategy.

**Our goal** is to be a high performing organisation with the right people, culture, processes and technology in place, and to achieve more through effective partnerships.

# The impact we had in 2022

We are able to effectively advocate for change for cancer patients because we have the networks, relationships and grassroots structures to do so. Deepening these structures is a part of our strategy, and in 2022 we increased the number of members of our Advocacy Champions Network from 29 to 44. We also continued to support the Oireachtas Cross Party Group on Cancer, a dedicated political group on cancer, bringing together 13 TDs and Senators from across the political spectrum. This group championed the “Right to be forgotten” Bill which was brought to the Oireachtas in 2022.

We are passionate about ensuring that our volunteers have the best experience with the Irish Cancer Society, and are recognised for their achievements. In 2022 we had over 3,000 active volunteers supporting the Society across all areas of our work. 490 new volunteers joined the Society volunteering their time across our charity shops, volunteer driver service, Relay for Life, survivor support and many more areas. We’ve improved our training and on-boarding of volunteers to help ensure they are equipped with all they need to make an impact.

2022 saw our first national volunteer conference, where nearly 200 volunteers came together in-person and online to share their experiences, learn more about the Society and celebrate their work. The Irish Cancer Society volunteers and staff were also recognised at the 2022 Volunteer Ireland Awards. The volunteer driver service took away the award for best Large Group, and we were honoured that our late colleague Carmel Murray (Murphy) was recognised as Volunteer Manager of the Year, for her support for Relay for Life across the country.

In order to best serve people affected by cancer, we need to attract and retain talented staff. In 2022, we were delighted to be recognised on the Sunday Independent/ Statista Best Employers List for the second year in a row, this year moving to 6th place nationally.

We are proud to be a good employer, and 2022 saw us further improve our people practices. For example, we introduced improved paid family leave policies including fertility leave and 12 weeks of paternity leave. We expanded too our compassionate leave policy, extending bereavement leave, introducing paid leave for

employees caring for loved ones at end of life, ensuring access to counselling and bereavement supports, and providing guidance for staff to support their colleagues through bereavement. We are also proud to have committed in 2022 to ensuring that all members of staff are paid the living wage, not just the national minimum wage.

We have continued to grow our online presence through social media expansion and through cancer.ie. We have ended 2022 with 265,000 social media followers across Facebook, Twitter, Instagram and LinkedIn (up 4% from 2021), and continue to engage the public with daily original and creative content. Over 1 million unique visitors also came to cancer.ie in 2022. (This is down 18% on 2021, but 2021 saw record numbers visiting cancer.ie to make donations following our Late Late Show Daffodil Day appeal).

265,000

Social media followers (Facebook, Twitter, Instagram and LinkedIn)

↑ Up 22% from 2021

294.7m

Media reach

↓ Down 2% from 2021



# Achieving our objectives

2022		
Objective	Results	Progress
<b>Expand the Grassroots Advocacy Network to all Dáil constituencies with all advocates trained and ready to drive change for people affected by cancer, and expand our network of online champions.</b>	The Grassroots Advocacy Network includes advocates at constituency and local level, and has grown from 29 to 44 members in 2022.	Achieved
<b>Implement changes to our internal processes to better utilise technology, increase efficiency, and improve the quality of the services we offer.</b>	We have introduced improvements to our project management processes, night nursing and volunteer driving services, and approaches for internal referral to services, and will continue to improve.	Achieved Goals for 2022 achieved, with further progress targeted in 2023
<b>Implement a brand refresh for the Society, to help raise awareness of our work and increase the number of people who avail of our services and supports.</b>	Work on this has been completed, and we will implement changes in a phased basis through 2023.	In progress
<b>Continue to grow our digital and online presence, and reach more people through our digital channels.</b>	Increased our social media following by 4% and saw engagement increase also. Visits to cancer.ie is down on 2021, but this is due to the exceptional traffic generated by 2021's Late Late Show special.	Achieved in part
<b>Begin implementation of our people strategy, including increased training, learning and development of staff and volunteers to retain talent and improve the work that we do.</b>	Commenced with new family leave policies, bereavement supports, staff inclusion training, wellbeing events and supports. Will continue into 2023.	Achieved Goals for 2022 achieved, with further progress targeted in 2023
<b>Recruit at least 200 new volunteers to support the growth of our services.</b>	490 new volunteers were recruited (this figure excludes shop volunteers and Daffodil Day street sales volunteers who are additional)	Achieved
<b>Support four meetings of the Oireachtas Working Group on Cancer throughout 2022.</b>	Three meetings of the group were held in 2022.	Achieved in part
<b>Establish a Grassroots Councillor Network for the Society to expand our advocacy reach into local communities.</b>	Recruitment for this network has started.	In progress



# Welcome



LIVING  
WELL WITH  
AND BEYOND  
CANCER  
CONFERENCE

Bridie Bowe, one of the many volunteers who supported the Society's survivorship conference.

## Our objectives for 2023

- » Continue implementation of the people strategy, to attract, retain and engage staff and volunteers.
- » Increase our focus on equality, diversity and inclusion and implement inclusion training and activities.
- » Recruit 500 new volunteers to the Society.
- » Celebrate the 60th anniversary of the Society and use this as an opportunity to raise awareness of our work.
- » Continue to grow our online and social media engagement.
- » Implement a new fundraising platform to improve the donor experience.
- » Update and continually improve our approach to GDPR, risk management and internal audit.

# HOW WE WORK



## Our volunteers and staff

The Irish Cancer Society community is made up of dedicated and hard-working staff, volunteers and supporters across every county in Ireland.

Our volunteers engage across all of the Society's work. They help deliver services such as the peer support programme, providing emotional and practical support to anyone going through cancer; the volunteer driver service, bringing patients to and from treatment; and our Daffodil Centres, providing information and support.

Our community of patient representatives also support researchers across the country, ensuring that the patient experience is reflected in the research we fund. Volunteers also work across fundraising initiatives like Daffodil Day, Relay for Life and assisting in our retail shops; and in our advocacy and communications work, championing

change and raising awareness. The Society's Board and committee members all serve in a voluntary capacity providing governance, oversight and expertise.

With the lifting of COVID-19 restrictions, 2022 was a year of transition for our staff and volunteers. We had our first full year of trading in our shops since 2019, as our staff and volunteers returned to the heart of communities across the country. Our previously office based staff transitioned to a new hybrid model of working, blending the best of in-person and remote working. As our Daffodil Centres reopened volunteers also returned. We also saw many volunteers who had taken a step back due to COVID-19 concerns return to volunteering.

Our network of supporters across the country also adapted once again, restarting in-person events and fundraising with renewed vigour. After three years being off the streets, it was almost overwhelming to see volunteers and staff back on the

streets for Daffodil Day 2022, painting the country yellow once again.

We are proud of the recognition shown to our staff members and volunteers in 2022, including at the Volunteer Ireland Awards and in the Sunday Independent/ Statista Best Employers List (see page 45).

Every day our staff and volunteers work with pride and commitment, embracing new ways of working, adapting to change and always retaining focus on doing the best that they can for people affected by cancer.

To our community of staff, volunteers and supporters, thank you for all that you have done in 2022, and every year, to support people affected by cancer in Ireland.





Left: The Cheng family at the Irish Cancer Society family camp in partnership with Barretstown; Middle: Attendees at the Society's survivorship conference; Right: Broadcaster Claire Byrne helps mark Daffodil Day 2022.

## Diversity and inclusion

Cancer affects everyone. And everyone affected by cancer deserves care, support and treatment that meets their unique needs, and gives them the best opportunity to live well with and beyond cancer.

We champion diversity and inclusion in all that we do, and continually look for ways to provide information and supports that meet the needs of all people in Ireland. We also seek to reflect inclusion across our community of staff, volunteers and supporters. Being an inclusive place to work and volunteer, and having diversity of backgrounds, communities and thought, strengthens the Society and benefits the people we serve.

A particular focus of our strategy is to reduce inequality of outcome and reduce the survival gap. Throughout our work we aim to reach and serve people experiencing social and economic disadvantage. Our focus

on reducing the cost of cancer, for example, particularly supports lower income families. We also bring our Your Health Matter roadshows to areas with higher rates of cancer and lower access to health services, to help reduce inequalities in cancer detection.

Accessibility of our information and services to people of all backgrounds and abilities is important to us. We use plain language across all of our information and communications. We also offer services, such as our patient education programmes, in multiple forms – in person, online, by phone, and through captioned video cards – to provide accessible options for people. Sign language interpretation is also available for callers to the Support Line.

In 2022, we reflected our value of inclusion across all our work, as well as launching new initiatives:

- » When Russia invaded Ukraine, we immediately put in place specific services to support people affected by cancer who were

forced to flee their homes and travel to Ireland.

- » We launched an interpretation service to allow people to access our supports and services through their first language. Callers to our Support Line or visitors to our Daffodil Centres can have a real-time conversation with a cancer nurse, which is translated live by an interpreter over the phone. Patients in need of other services, such as volunteer driving, are also supported by interpretation to make appointments and access support in their native language.
- » We partnered with the Capuchin Centre to provide free health checks and cancer awareness information to users of their day service. This allows us to provide support and care for marginalised members of the community.
- » We worked with Precision Oncology Ireland for the third year running on the Invisible Spectrum Initiative which aims

- » to engage minority communities in science and cancer research. This year we worked with them on initiatives to engage Bangladeshi and Arabic Muslim community groups.
  - » We continue to promote good health literacy through our new patient empowerment videos and healthcare professional e-learning resource. This is a partnership with the National Adult Literacy Association (NALA) to support people of all backgrounds to be able to understand and access health information.
  - » We piloted a staff inclusion training programme, including training on intercultural awareness, Traveller and Roma inclusion, and gender equality.
  - » Our nurse team leaders worked with LGBT Ireland to become LGBT Champions, and rolled out training to all our Daffodil Centre and Support Line nurses.
  - » We held a series of events for LGBT+ Pride Week, including attending at Dublin Pride, to celebrate the LGBT+ community and increase staff and volunteer understanding of the experiences of LGBT+ people.
  - » Trans Equality Network Ireland (TENI) provided staff training on trans awareness, with a particular focus on the issues facing trans and non-binary people in accessing healthcare.
  - » We increased the paid family leave offered to staff, including paternity leave, in order to support the needs of working parents and to promote gender equality.
  - » We published our gender pay gap report, and identified ways that we can improve gender equality in our work.
- In 2023 we will complete our funded research into the particular needs of marginalised communities, and identify new ways to reach people and provide support. We will also launch an internal diversity, equality and inclusion (DEI) group to advance DEI initiatives across the Society. We will continue to increase our understanding, and will expand our pilot inclusion training programme to all staff.
- Whoever you are, wherever you come from, we are here for you.

## Supporting the Ukrainian community

8 million Ukrainians are estimated to have sought refuge across Europe, following the Russian invasion in February 2022, with over 70,000 people coming to Ireland. Among these were children and adults with cancer who needed to continue their treatment here.

For Ukrainian refugees affected by cancer, they have been forced to leave their homes, their clinical care and their support network, all while going through one of the most devastating experiences of one's life.

The Irish Cancer Society immediately stepped up to provide help and support, including in their native language, for those Ukrainian refugees who are impacted by cancer

We immediately convened a meeting of senior clinicians and National Cancer Control Programme to co-ordinate the response for refugees arriving in Ireland who need access to cancer services, and joined the European Cancer Organisation's Special Network of the Impact of the War in Ukraine on Cancer to coordinate at a European level.

We appointed a Ukrainian Cancer Coordinator, from Ukraine, who provided individual support to patients and families here in Ireland. She worked with families from March until September, when the HSE's services were able to provide this support.

We translated cancer information into Ukrainian, and launched a dedicated information section on our website, in Ukrainian and English, to help people navigate the Irish health system. Live translation services were also put in place so that anyone speaking to our Support Line and Daffodil Centre nurses is able to access information and support through Ukrainian.





Shane Filan, the official ambassador for the Irish Cancer Society Relay for Life.

## Sustainability

The health of our planet and human health are deeply interlinked, but often overlooked. We are proud to be a member of the Climate and Health Alliance, a group of public health organisations, charities and advocacy groups from across the island of Ireland. Together we are working to raise awareness of the links between health and climate change, and campaign for action to address the climate crisis.

As an organisation, we are committed to working in the most environmentally sustainable way possible, for the good of our planet and its people. We have taken steps in our everyday actions, reducing paper consumption and printing; and ensuring the re-use or recycling of our waste wherever possible. Our electricity supply is 100% renewable, and we have invested in energy efficient fixtures and equipment.

Our offices are free from single-use plastic, and we keep these materials to a minimum at our fundraising and other events. We promote active travel for our staff, and the public generally, as well as use of public transport for business travel where possible.

The increase in remote working, brought about by COVID-19, had the impact of reducing our waste production, and water, paper and energy consumption, as well as reducing the carbon impact of staff commuting. As we moved to hybrid working in 2022, we retained this where possible and have reduced waste, water and paper consumption and energy use in 2022 as compared to pre-pandemic.

The Society also operates 21 charity shops across the country, which contribute to the circular economy by diverting clothes and household goods from landfill.

## Our partnerships

Collaboration is a core value of the Society. Working together with partners across the cancer community we can better achieve our vision and mission.

We work with other health charities and public health organisation to promote and support policies which enable people to live a healthy life. We are members of the Alcohol Health Alliance and part of the Tobacco Free Ireland partner group, working to reduce the health risks from smoking and excessive alcohol consumption.

We also work with other charities and cancer organisations, to avoid duplication of effort and to expand what we can offer to people in Ireland. In 2022, we continued our partnerships with CRUK and CCLG, two UK based cancer charities, to customise their cancer information







Top: Members of the Oireachtas Cross-Party Group on Cancer with Director of Advocacy and External Affairs, Rachel Morrogh, at the publication of the group's legislation on the "right to be forgotten". Bottom: Nimbe and Niall at the Irish Cancer Society young adults' camp, in partnership with Barretstown.

# FUNDRAISING REVIEW

2022 saw a “new normal” begin to emerge for fundraisers and donors, and our fundraising generally. Daffodil Day 2022 was a momentous occasion, as supporters returned to the streets for the first time since 2019.

Despite a reduced lead in time to prepare for on street activities, due to the late lifting of restrictions, and some normal participation among the public and corporate supporters being curtailed due to COVID-19, Daffodil Day 2022 was the second most successful in the Society's history.

Over the course of 2022, €19.8million was raised through donations, legacies and fundraising campaigns.

The “COVID bump” of 2021 which was seen across the sector disappeared but in its place we have new processes and optimisation of our message which we developed during the pandemic years. This enabled the organisation to continue with revenue growth in new ways even as some fundraising trends continue to decline.

## Achieving our objectives


### Our objectives for 2022 were to:

- » Continue to optimise all channels to make supporting the Irish Cancer Society a seamless user experience.
- » Continue to redevelop the Daffodil Day campaign in line with new consumer behaviour and trends.
- » Deepen existing corporate partnerships with new offerings, and impact and develop new corporate relationships.
- » Develop our major donor, legacy and regular giving strategies in line with an overall need for sustainable fundraising.
- » Improve the data available to the fundraising team, and identify and target specific segments more efficiently.

We made progress across all these areas, including adapting our Daffodil Day campaign, advancing new corporate partnerships, and improving our user experience and internal processes to improve our operations.



Top left: Irish jockey Rachel Blackmore supporting Daffodil Day. Bottom: Donegal locals Rachel Akkoç and her son Ziya who took part in our Daffodil Day television advert. Top right: The 2022 Women's Mini Marathon.







## How we did

Daffodil Day in March generally sets the tone for fundraising for the Irish Cancer Society across the year. In early January 2022, there were still some COVID-19 restrictions in place. Our traditional community gathering in advance of Daffodil Day couldn't take place and many volunteers understandably decided not to partake in the day until they felt safer out in public. In addition to this a significant amount of the media agenda and fundraising attention went towards the war in Ukraine, which required a national and international response. This did however impact funding and donations available from the public and corporate partners.

A lack of physical cash in people's pockets and the changes in working from home rather than urban centres were also concerns for Daffodil Day

2022. However, identifying digital means to donate on-street and our partnerships ensured there was a warm and dedicated Daffodil community.

Despite challenges, the work and investment we had put into data capture and engagement of Daffodil Day audiences from 2021 resulted in a healthy 2022 Daffodil Day. A total of €4.7 million was raised across the campaign – the second most successful Daffodil Day ever.

A return to door-to-door and private site fundraising meant the Irish Cancer Society could re-engage with its strategy around regular giving. The public appeared content to re-engage with these formats and acquisition targets continued to be met.

Meanwhile, many of our best loved events including Relay For Life, Moylagh JFK and Hurling for Cancer Research, were able to return fully

in person for the first time, bringing the joy and comradery back to our community.

Elsewhere the mix of fundraising changed as society opened up and new consumer habits were formed. The cost of fundraising was also driven up in 2022 due to rises in inflation including cost of media, printing, merchandise, delivery and staff. Meanwhile, the cost of living crisis in the backend of 2022 meant some supporters and corporate partners were not able to give as much as they previously had.

## Campaigns

Some campaigns such as Splash a Day and Marathon In a Month were impacted by return to office based working and post-COVID activity fatigue. This was seen across the sector as employees returned to in-office working and had less free time

to support as well as feeling less urgency to do so.

Relay for Life events across the country returned throughout the summer much to the delight of the very committed Relay for Life community. We are committed to growing Relay for Life, and worked in 2022 behind the scenes to advance this. We were delighted to announce in early 2023 that Shane Filan from Westlife is our new Relay for Life Ambassador, championing Relay for Life in 2023 and beyond.

In Autumn 2022, the "Care for Your Pair" breast cancer campaign exceeded targets with Big Pink Breakfasts across the country, a new media partnership and some significant corporate support.

Christmas brought a season of goodwill from supporters who responded to our campaign by purchasing donation cards, Christmas ornaments and providing general donations.

## Corporate

2022 continued to widen corporate support for the Society. We are grateful for continued and new support from companies such as Centra, Primark, Aldi, Pfizer, Leinster Supporter's Club, Kilkenny Design Store and Boots. Yet again Revolut contributed to the overall success of Daffodil Day and generated good results across World Cancer Day with their donations and support resulting in a combined income of over €400,000.

## Major donors

In 2022, we were grateful to receive a major donation of €1 million. In addition, we also saw a year-on-year increase in major donations generally. We have made good strides to deepen our engagement with our current major donors and to secure new trust and foundation grants.

## Digital giving

Facebook tribute gifts which, at their peak, once generated about €1 million for the Society are in

significant decline as a mode of giving. Throughout 2022 we optimised this channel as much as we could but also tested new ways to encourage donations through the larger digital platforms.

## Community fundraising

The return to in-person events saw some of our most loved community events back again with fantastic participation. Some highlights included the Moylagh JFK walk, the Mac Norman Tractor Rally and the Inishannon Steam and Vintage Rally.

The final income for Dublin Marathon was €420,000 making it the most successful Dublin Marathon ever for the Society, more than doubling the previous highest amount taken for that campaign.

Hurling for Cancer Research also returned, with thousands of people back in St. Conleth's Park in Kildare for the first time in three years. Many well-known sports stars turned up to show their support, and over €130,000 was raised.

## Committed giving

Despite the challenges of a cost of living crisis and two banks exiting the Irish market, regular giving acquisition and attrition remained stable. We worked to steward donors with Ulster Bank and KBC accounts to renew their regular gift with their new accounts.

The ability to return to door to door and private sites meant the Society could also recruit new regular donors. We also continued to respond to an ever challenging market with diversified product offerings and emotionally engaging content.

## Special appeals

Special appeals delivered 14% over budget with donors responding to increasingly optimised targeting and impactful communications. This was as a result of our focus on donor experience and the generous and brave survivors and families who shared their personal stories.

## Our objectives for 2023

- » **Maintain growth in our fundraising targets while being conscious of current consumer sentiment.**
- » **Deepen the engagement with corporate partners and understand new employee engagement methods.**
- » **Continue to develop brand prominence to keep the case for support front and centre.**
- » **Diversify portfolio of products while transitioning some traditional products.**
- » **Optimise donor data to deliver best in class donor experience.**



Above: Hugo Keenan, Josh van der Flier, Irish Cancer Society CEO Averil Power, Andrew Porter, James Ryan and Garry Ringrose at UCD Rugby's 2022 Daffodil Day launch. Top left: Members of the ukulele band The Walkeleles fundraising in Dublin city centre. Top right: Daffodil Day ambassador Mick McCarthy visiting volunteers on Dublin's Grafton Street. Bottom: The annual Hurling For Cancer Research Charity Match which took place in St Conleth's Park, Newbridge.







# FINANCIAL REVIEW

2022 was a challenging year for the Irish Cancer Society, as for many Irish organisations. Rising inflation and energy costs placed pressure on the Society's expenditure base. The cost of living crisis alongside competing demands on the public's disposable income created uncertainty in the fundraising environment. In spite of this, the Society managed to maintain income in 2022 at the same level as 2021.

This was achieved through a return of traditional fundraising methods that had not been possible for the previous two years due to COVID-19 restrictions and by continuing the focus on new digitally led fundraising and income streams which had been developed in recent years.

Thanks to the efforts and generosity of supporters, volunteers and employees, the Society succeeded in securing total income of €26.6m.

In 2022, the Society's total income was €26.6m (2021: €26.6m). The Society's total expenditure was €27.1m in 2022 (2021: €23.1m), an increase of €4.0m (17%) on prior year.

## Income

The vast majority of 2022 income came from the generous support of the public, through fundraising campaigns, donations, legacies and charity shop sales. Grants from the State represented only 5% of the Society's total income (2021: 3%).

Income	2022	2021
Donations and legacies	€19.8m	€22.0m
Trading activities	€4.2m	€2.5m
Charitable activities	€2.4m	€1.7m
Other and investment	€0.2m	€0.4m
<b>Total income</b>	<b>€26.6m</b>	<b>€26.6m</b>

On 25 March 2022, for the first time since 2019, the Society ran a successful community and street based Daffodil Day event, which raised a total of €4.7m in income (2021: €7.9m).


### Donations and legacies

Income from donations and legacies in 2022 was €19.8m. This was €2.2m lower than in 2021.


### Donations

The Society received €17.4m in donations in 2022 (2021: €19.7m), a 12% decrease on 2021. 2022 saw a return of in-person community and street based fundraising campaigns. The 2022 Daffodil Day campaign proved to be the second most successful one in the Society's history, raising a total of €4.7m (2021: €7.9m). Other national campaigns

## 2022 donations and legacies



## Donations 2017-2022



and donations contributed a total of €5.5m in 2022 (2021: €6.4m). The Society managed to grow its 2021 level of individual giving income to €3.2m (2021: €3.1m); this was due to a number of successful special appeal campaigns, and a renewed investment in the Society's door-to-door individual giving programme. Income from philanthropy and corporate partnerships totalled €4.0m in 2022, a 64% increase on 2021; a donation of €1.0m that was restricted to the Society's Children, Adolescent and Young Adult (CAYA) services fund was received by the Society in 2022. Overall, in spite of the challenging economic situation, and the competing demands on the public's disposable income, the Society successfully managed to grow its total donations compared with 2019 (the most recent pre-COVID-19 year) by 11%; this was achieved across many income streams, and thanks to numerous innovative fundraising initiatives.

The Society's donations have been increasing steadily since 2017, with the exception of the two years that were impacted by COVID-19 restrictions. 2020 showed a significant decrease due to fundraising efforts having been curtailed with no time to plan, while 2021 showed a significant increase, due to a number of successful once-off fundraising initiatives. 2022 was the first year, since 2019, that the Society ran traditional face-to-face events.

### Legacies

The Society's income from legacies was €2.4m in 2022, an increase of €0.2m on 2021. In 2021 the Society benefited from one legacy greater than €0.3m in value, where as in 2022 the Society benefited from two legacies greater than €0.3m in value.

### Trading activities

Income from the Society's 21 (2021: 21) charity shops increased by €1.6m (68%) compared to 2021. This was due to the shops having been closed for five months in 2021 due to COVID-19 restrictions. The shops were open throughout 2022. Overall, the charity shops contributed a net surplus of €1.0m in 2022 (2021: €0.2m).

### Charitable activities

Income from charitable activities of €2.4m was €0.8m higher than in 2021. This income includes grants from the HSE to support the Society's Travel2Care and Night Nursing programmes, and reimbursements for Night Nursing services provided. In 2022 the Society received additional grants from the HSE totalling €0.7m in relation to its Night Nursing programme.

### Other income

Other income of €0.1m was €0.2m lower than in 2021. This was due to the Society having availed of a COVID-19 related government Restart Grant scheme in 2021, but not in 2022.

Income from government agencies represented 5% of the Society's total income in 2022 (2021: 3%).

## Expenditure

In 2022, the Society spent €27.1m (2021: €23.1m) in furtherance of its goals.


Expenditure	2022	2021
Charitable activities	€18.3m	€16.1m
Fundraising activities	€5.7m	€4.7m
Trading activities	€3.1m	€2.3m
<b>Total expenditure</b>	<b>€27.1m</b>	<b>€23.1m</b>

For every euro spent by the Society, 76c (2021: 77c) went on charitable activities (not including trading activities). A further 24c (2021: 23c) was spent by the Society to raise money to fund its charitable activities. This increase was due to additional spend on the individual giving programme in 2022, and an increased investment in the Daffodil Day appeal. There were limitations in 2021 in relation to these particular expenditure areas, as a result of COVID-19.


### Charitable activities

Expenditure in relation to charitable activities in 2022 was €18.3m (2021: €16.1m), an increase of €2.2m (14%) in relation to 2021. This increase was due to the Society having spent an additional €0.3m in relation to its Volunteer Driver services (activity for this service rose by 30% from 2021), an additional €0.2m in relation to financial assistance grants for families with children affected by cancer, and an additional €0.2m in relation to its Night Nursing service. The Society

## 2022 fundraising campaign direct expenditure



## Charitable activities expenditure 2017-2022



also established a new community-based hub service at a cost of €0.4m, and services dedicated to Children, Adolescents and Young Adults (CAYA) at the cost of €0.4m.

The Society has been increasing its charitable activities spend since 2018, in line with its strategic goals, and it is expected that this trend will continue.

### Fundraising activities

€5.7m was spent on fundraising activities (2021: €4.7m), an increase of €1.0m (20%) on 2021 expenditure. This increase was due to the Society increasing its efforts in promoting fundraising campaigns, especially Daffodil Day, and increasing its investment in its individual giving programme.

For every euro spent on fundraising activities in 2022, the Society raised €3.50 in donations and legacies (2021: €4.60).

### Support costs

Support costs are costs which cannot be directly attributed to a particular activity and have been allocated accordingly. These include costs relating to technology, human resources, finance, governance and other central functions. These services play a crucial role in providing core organisational support in the delivery of the Society's charitable goals. The total support costs for the year were €3.6m (2022: €2.9m). The main drivers for the increase in costs was an investment in the Society's IT infrastructure and the development of a team focused on volunteer management; these costs were incurred in line with the Society's strategic goals.

### Trading activities

Trading activities spend was €3.1m, which was an increase of €0.8m (37%) on 2021. The increase in cost was due to the shops having been

open for a full year in 2022, and for only seven months in 2021.

## Financial position and reserves policy

The Society's reserves policy is to hold adequate reserves so that it can continue to provide critical services through challenging economic times, as well as be in a position to take advantage of unexpected opportunities to improve the lives of those affected by cancer.

An adequate and working reserves policy provides essential accountability to the Society's beneficiaries, public supporters and other stakeholders, and assures them that the Society's activities are sustainable.

The Society's reserves policy aims to minimise liquidity risk. The Society holds a portion of its reserves on deposit with reputable financial



institutions. Funds that are not required for operational purposes in the medium term are managed by the Society's investment advisors and invested in marketable securities.

The Society regularly monitors levels of cash and investments to ensure that it can meet its expenditure commitments.

The Finance Committee regularly assesses the counterparty risk with institutions that hold Society funds. In addition, the Finance Committee reviews annually the allocation of funds to the investment portfolio.

The Society seeks to maintain an amount equivalent to approximately six months' of annual expenditure in cash and investments. However, the actual amount maintained in cash and investments will vary depending on short and medium-term needs, as well as on income forecasts and the prevailing economic climate.

The available resources at 31 December 2022 were €31.9m (2021: €33.9m). Of this, €0.9m (2021: €0.4m) was held in restricted funds, as the funds were donated for specific purposes. €31m (2021: €33.5m) was held in unrestricted funds; €1.0m (2021: €1.0m) of this was held in designated funds. At 31 December 2022, the Society held 11.8 months on a €30m expenditure basis (31 December 2021: 12.2 months on a €30m expenditure basis) of expenditure in cash and investments. The €30m expenditure basis reflects the budgeted spend for 2023. This level of cash and investments allows expenditure on new programmes under the ambitious 2020-2025 strategy. The Society has budgeted for a deficit in 2023, and based on its five-year financial plan, budgets to incur significant deficits over the next five years as it invests in a number of new initiatives to improve the lives of those affected by cancer. It is expected that by the end of 2027 the Society will be balancing its income and expenditure, and its cash and investments balance will be in line with its target. The current level of reserves will enable the Society to continue to deliver critical services to those affected by cancer, despite the current uncertain economic environment.

### Designated funds

The €1.0m fund at the year-end relating to research was held to protect currently committed research programmes from future unexpected variations in income. The time horizon on research programmes is typically three to five years.

### Investment policy and performance

The Society's main investment objectives are:

- » To preserve the value of its investments.
- » To maintain the real value of its investments against inflation.

The Society engages the services of suitably qualified investment advisors to provide unbiased and impartial investment advice in accordance with the investment policy. The Society's investment advisors manage the Society's investment portfolio on its behalf, and are responsible for considering all financially material matters in relation to the selection, retention, and realisation of investments.

The Society mandates its investment advisors to ensure that the Society's investments are in line with established responsible investment principles. The Society's responsible investment strategy is to enhance the long-term value of its investments by managing environmental, social and governance risks, whilst balancing risk and return, with capital preservation taking precedence over potential return. In addition to this, the Society has a policy of excluding investments in certain types of securities that are contrary to the Society's charitable mission.

All of the Society's investments are held in securities that can be converted to cash promptly.

The Society's attitude to risk in respect of its investment portfolio is low to moderate.

The Society seeks to maintain an amount equivalent to approximately 6 months of annual expenditure in cash and investments; on a €30m annual expenditure basis, this would

be €15m. However, the actual amount maintained in cash and investments will vary depending on short and medium-term needs, as well as on income forecasts and the prevailing investment climate.

A review of both the reserves and investment policies is conducted regularly. During 2022, the Society's invested funds yielded an average return of -18.2% (2021: +12.9%). There was a loss on investments of €1.5m in 2022 (2021: gain of €0.9m).

### Accounting records

The Directors have taken the following measures to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records: the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The Society's accounting records are maintained at the Society's registered office at 43/45 Northumberland Road, Dublin 4.

### Disclosure of Information to auditors

In the case of each of the persons who are Directors at the time, the Directors' report and financial statements are approved:

- » so far as the Director is aware, there is no relevant audit information of which the Society's auditors are unaware; and
- » each Director has taken all steps that ought to have been taken by the Director in order to make himself/herself aware of any relevant audit information and to establish that the Society's auditors are aware of that information.

The auditors, Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, continue in office in accordance with Section 383(2) of the Companies Act 2014.

# STRUCTURE, GOVERNANCE AND ORGANISATION

## Organisational structure

The Irish Cancer Society is a company limited by guarantee and registered as a charity with the Charities Regulatory Authority. The Society is governed by its Constitution which provides for a member-based organisation with the following charitable aims:

- » to foster, promote and advance the relief, cure, treatment, prevention, lessening and alleviation of cancer or any disease of an allied or similar nature;
- » to promote research devoted to the study of the origin and causes, relief, cure, treatment, prevention, lessening and alleviation of cancer, or any disease of an allied or similar nature.

The Irish Cancer Society has a subsidiary company, Irish Cancer Society Research Limited, which was incorporated in Ireland in 1991. The company ceased trading at the end of 2013. The company currently has two Directors – Ger Penny and Allan Kearns – who were appointed on 5 March 2020 and 1 July 2021 respectively.

## Members

There are currently 46 members of the Irish Cancer Society, 10 of whom are Directors. Each member guarantees to contribute up to one euro twenty-seven cent (€1.27) to the Society's debts, liabilities and costs in the event of it being wound up.

## Board of Directors

The Society has a voluntary Board of Directors which meets approximately six times per year. The Directors are responsible for the governance and overall oversight of the organisation and its activities.

The Board delegates day-to-day operational management to the Chief Executive Officer, Averil Power, who is supported by the Executive Leadership Team ("Management").

The Board manages its work through a number of committees, comprising Directors and external volunteers, each of which is chaired by a Director of the Board. The Society values the benefits of having committee members from a diverse range of backgrounds, expertise and experience.

All Directors and committee members are non-Executive and do not receive fees for their contribution to the Society, however, out-of-pocket expenses may be claimed.

### Appointments/Retirements

Directors ordinarily serve for a maximum of six years. This can be extended by the Board in exceptional circumstances by a further three years, if such extension serves the best interests of the Society. Board committee members are appointed for three years, extendable by a further three years, at the discretion of the Board.

The Chair of the Board is elected annually, by the Board, for a maximum term of three years, which can be extended by a further one year in exceptional circumstances.

Each year one third of Directors are subject to retirement by rotation. In 2022, Prof Sinead Brennan, Dr Cormac Kilty and Irene O'Gorman offered themselves for re-election and were duly re-elected. In September 2022 Kieran Crowley retired from the Board.

Director nomination and recruitment is overseen by the Board Effectiveness Committee. The Committee undertook a Board skills review in 2022, and following on from this, recommended to the Board the

recruitment of an additional Board member. On 1 September 2022, Maria Fleming was appointed to the Board from the Finance Committee.

The Board extended the tenure of three Directors serving over six years, by one year – Prof Liam Grogan, Prof Sinead Brennan and Dr Cormac Kilty. The extensions were made due to their particular medical and cancer research expertise, and to allow time to find suitable replacements.

Conor King resigned as Company Secretary in March 2022, and Emma Browne was appointed in his place.

### Induction

All new Directors receive a comprehensive induction, overseen by management. Directors meet with the Chair, the CEO, and other members of the Executive Leadership Team. During their induction they receive an overview of the Society's activities, the strategic plan, an outline of their regulatory and statutory duties, and the Society's governance framework.

Board training is considered by the Chair and CEO annually. Board members attend external training as appropriate and are also provided with briefings from the Executive Leadership Team throughout the year. In June 2022 a training session on fundraising and the cancer landscape was held for the Board.

### Board evaluation

The Board reviews its own effectiveness each year and commissions an external Board evaluation every three years. In 2020 an independent external Board evaluation was conducted, and a new evaluation will be commissioned in 2023. In late 2022, the Board Effectiveness Committee oversaw a Board self-evaluation to assess Board efficiency and effectiveness. The survey results rated all areas as above average.

## Good governance

Good governance is fundamental to our sustained success as a charity. The Society operates a culture of constant improvement in relation to our governance procedures and policies. In 2020 we developed our Governance Manual; restructured our Board committees and re-drafted their terms of references; established a Board tenure policy; and strengthened our induction process. In 2023 the areas of focus for the Board were reviewing the conflict of interest policy, diversifying the Board, Board succession and a Board training session.

## Conflict of interest

The Society has a conflict of interest policy and all Directors and external committee members sign a conflict of interest form annually. Conflict of interest is a standing agenda item at all Board and committee meetings. If a Director or a member has a conflict of interest they must declare it, and a judgement will be made on the most appropriate course of action given the materiality and nature of the conflict. In 2022 the Board Effectiveness Committee reviewed the conflict of interest policy and benchmarked it against the Charities Regulator guidance. The Committee recommended amendments which were subsequently approved by the Board and the AGM. In addition, Directors sign a register of interests declaration annually declaring their interests, and a register of interests is maintained by the Company Secretary.

There were no instances or arrangements during 2022 whereby a Director was materially interested in the Company's activities.

## Meetings held

The following Board and committee meetings were held in 2022:

Meetings held	
Board of Directors	7
Finance Committee	6
Audit and Risk Committee	3
Board Effectiveness Committee	1
Research Advisory Committee	2

The following table shows Directors for the financial year 2022 and their attendance at Board meetings during the year. In addition, it shows Directors' appointment and retirement dates (where applicable).

Director	Attendance	Date of appointment	Date of retirement
<b>Brid Horan (Chair)</b>	7 of 7	13 Jul 20	
<b>Prof Liam Grogan</b>	5 of 7	22 Nov 12	
<b>Kieran Crowley</b>	4 of 4	02 Oct 14	15 Sep 22
<b>Dr Cormac Kilty</b>	7 of 7	19 Feb 15	
<b>Dr Sinead Brennan</b>	6 of 7	01 Sep 16	
<b>Ger Penny</b>	5 of 7	05 Mar 20	
<b>Alex White</b>	6 of 7	25 Mar 20	
<b>Irene O'Gorman</b>	5 of 7	25 Mar 20	
<b>Allan Kearns</b>	7 of 7	01 Jul 21	
<b>Dr Mary Canavan</b>	6 of 7	8 Sep 21	
<b>Maria Fleming</b>	4 of 4	1 Sep 22	

## Executive leadership team

The Management team is led by Chief Executive Officer, Averil Power, and they manage day to day operations of the Society.

The current Management team is made up of the following positions:

- » CEO, Averil Power
- » Director of Services, Corrinne Hasson
- » Director of Advocacy and External Affairs, Rachel Morrogh
- » Director of Fundraising and Engagement, Fionnuala O'Leary
- » Director of Finance and Corporate Services, Jennifer Owens
- » Director of People, Strategy and Innovation, Anne Byrne

Matters such as policy, strategic planning and budgets are drafted by Management for consideration and approval by the Board, which then monitors the implementation of these plans.

## Board committees

In 2020 the Board oversaw a review of its Board committee structure to ensure alignment with the Society's new Strategic Plan 2020-2025. The Board delegates specific responsibilities to the Board committees, each of which has a detailed terms of reference and reports to the Board. Each committee is chaired by a Board member, has at least one other Director as a member, and can co-opt external committee members as required.

In 2022, a remuneration working group met once, to oversee a review of CEO and ELT pay and report to the Board.

## Finance committee

The Finance Committee exercises, on behalf of the Board, supervisory oversight of all aspects of the Society's finances. It monitors financial performance and oversees management of the investment portfolio on an ongoing basis. It also reviews the annual budget for recommendation to the Board.

**Report of 2022 activity:** During 2022, the Finance Committee monitored the Society's monthly management accounts, income and expenditure trends, investment performance, financial projections



and reserve levels. It oversaw the 2023 budgeting process, and was notified of any significant payments and commitments. Additionally, the Committee reviewed the trading performance of the Society's twenty-one charity shops.

#### Finance Committee attendance 2022

<b>Ger Penny (Chair)</b>	5 of 5
<b>Irene O’Gorman</b>	3 of 5
<b>Maria Fleming</b>	5 of 5

#### Audit and Risk Committee

The Audit and Risk Committee assists the Board in fulfilling its responsibilities by independently reviewing the annual financial statements, overseeing the external audit, reviewing the effectiveness of the Society's internal controls, as well as adherence to the Charities Regulators Governance Code. It also monitors the Society's risk management, oversees regulatory and legislative compliance, and provides an assessment of risk processes and policies to the Board.

**Report of 2022 activity:** The Committee oversaw the Society's relationship with their external auditors, Deloitte. This included reviewing the audit work plan, considering Deloitte's key findings, including recommendations on internal controls, and ultimately recommending the Annual Report to the Board. The Committee also reviewed the Society's risk register and the Society's cyber security position. In addition, they oversaw a review of the Society's compliance with the Charities Regulator Governance Code, and its statutory obligations as a s. 39 organisation.

#### Audit & Risk attendance 2022

<b>Allan Kearns (Chair)</b>	3 of 3
<b>Dr Cormac Kilty</b>	3 of 3
<b>Alex White</b>	2 of 3

#### Board Effectiveness Committee

The Board Effectiveness Committee oversees the nomination, recruitment, and on-going training, as necessary,

of Directors. It also supports Board and committee effectiveness.

**Report of 2022 activity:** The Committee considered Board and committee succession planning and reviewed the Board skills and composition, recommending the recruitment of a new Director to the Board. It reviewed the Board Conflict of interest policy and made enhancements to align it with the Charities Regulator guidance. Additionally, it circulated a Board self-evaluation survey to the Directors.

#### Board Effectiveness attendance 2022

<b>Brid Horan (Chair)</b>	1 of 1
<b>Ger Penny</b>	1 of 1
<b>Dr Cormac Kilty</b>	1 of 1
<b>Allan Kearns</b>	0 of 1
<b>Conor King* (Company Secretary)</b>	1 of 1
<b>Averil Power (CEO)</b>	1 of 1

* Conor King resigned as Company Secretary in March 2022, and was replaced by Emma Browne.

#### Research Advisory Committee

The Research Advisory Committee reviews and evaluates the research activities and investments of the Society to ensure that they are achieving the objectives set out in the Society's strategic plan. It also ensures that the activities of the research department are in line with the national and international cancer research landscape, in addition to emerging clinical and patient needs.

**Report of 2022 activity:** The Committee met twice in the year. It reviewed the activities and plans for the research department, advised the Board on research elements in the strategy and reviewed the research budget for 2023. The Committee oversaw the implementation of the second year of our five-year research roadmap. It also provided guidance to the Society on how to make research investments that provide the greatest impact to those with cancer.

#### Research Advisory attendance 2022

<b>Dr Cormac Kilty (Chair)</b>	2 of 2
<b>Prof Sir Alex Markham</b>	2 of 2
<b>Dr Susan Gapstur</b>	2 of 2
<b>Prof John Reynolds</b>	2 of 2
<b>Dr Mary Canavan*</b>	2 of 2

* In January 2022 Eileen O’Sullivan rotated off the Committee and Dr Mary Canavan was appointed in her place.

#### Commitment to best practice in corporate governance

The Board operates to the highest governance standards and codes of conduct. A strong governance culture ensures that the Society is best placed to deliver on its mission and achieve its objectives. This is achieved by a continual focus on the Society's statutory and regulatory obligations, regular risk reviews, and by promoting a compliance-centric culture throughout the organisation.

During 2020 a detailed analysis of the Society's compliance with the Charities Regulator Governance Code was undertaken. As required by the Regulator, the Society will continue to review compliance on an annual basis. In 2022 the Board reviewed the Society's compliance status and was satisfied the Society is compliant with the Governance Code, Guidelines for Charitable Organisations on Fundraising from the Public and Internal Financial Controls Guidelines for Charities. The Society reported compliance with the Governance Code to the Regulator. Furthermore, in 2022, a review to assess the Society's compliance with their section 39 obligations was undertaken.

In addition, the Society is compliant in the following areas:

- » Compliant with relevant obligations under the Companies Act 2014 and the Charities Act 2009.

- » Compliant with the Charities Institute Ireland triple lock standards.
- » Annual Report is in accordance with FRS 102 and Charities SORP.

### Directors' compliance statement

The Society is required to prepare a Section 225 Compliance Statement (Companies Act 2014), for 2022, and as a matter of best practice commits to making this compliance statement annually.

The Directors acknowledge that they are responsible for securing compliance by the company with its relevant obligations as set out in Section 225 of the Companies Act.

The Directors further confirm that there is a compliance policy statement in place setting out the company's policies which, in the Directors' opinion, are appropriate to ensure compliance with the company's relevant obligations.

For the year ended 31 December 2022 the Directors, with the assistance of the Audit and Risk Committee, have conducted a review of the arrangements and structures in place. Arising out of this the Directors can confirm that appropriate arrangements and structures are in place which, in the opinion of the Directors, are designed to secure material compliance with the company's relevant obligations.

### Risk management and internal control

The Society's risk management process is supported by its governance structure. Whilst the Directors are responsible for ensuring there is effective risk management and an appropriate internal control environment, Management are responsible for the day-to-day operation of its risk processes. Management monitors the level of risks on an ongoing basis and the Board reviews this regularly.

As part of the risk management process an annual risk review is undertaken. The aim of the review is to ensure that the Society is not exposed to an unacceptable level of preventable risk and to identify risk mitigation strategies. Each risk was assigned to a relevant member of the Management team, reviewed by them, and updated with appropriate mitigation strategies. The updated 2022 risk register was then considered by the Audit and Risk Committee and reported to the Board. The risk management policy and risk register template is scheduled for a full review in 2023.

Annually, the Audit and Risk Committee consider the internal audit needs of the Society, based on our risk management process and the results of the external audit, and selects the relevant controls for independent testing. The internal audit function is led by our legal and compliance function. Where appropriate, staff, who have the relevant expertise, may be seconded to conduct internal audit activities. Otherwise, it may be outsourced to a third party provider under the supervision of the Audit and Risk Committee.

As an organisation we have a zero tolerance attitude to fraud. The Society minimises the risk of fraud through a strong internal control environment, a compliance culture, staff training on fraud and a whistleblowing system. In 2022 no instances of fraud came to the attention of Management or the Board.

**//**  
**The Board operates to the highest governance standards and codes of conduct. A strong governance culture ensures that the Society is best placed to deliver on its mission and achieve its objectives.**

The following are the top five risks identified in 2022.

### 1. Failure to meet the changing needs of cancer patients:

The risk that the Society will fail to respond and adapt to cancer patients' needs in the current environment.

#### Mitigation measures

- » Growing our feedback mechanisms with patients and key stakeholders.
- » Evaluation of our Services and conducting impact monitoring.
- » Continued expansion of our services in 2023 to meet cancer patients' needs.
- » Regular contact with key State stakeholders.
- » Continued tracking and monitoring of health appointment attendance, and cancer detection and diagnostic waiting times.
- » Funding research to understand changing needs.
- » Timely and effective media campaigns.

---

### 2. People risk:

The risk that the Society will not be able to attract and retain talent at all levels including staff and volunteers.

#### Mitigation measures

- » Ensuring the Society offers an attractive and competitive employer proposition.
- » Implementation of the Society's people strategy and investment in staff development.
- » Workforce and succession planning and ongoing monitoring of critical areas.
- » Flexible working, wellbeing programme and employee benefits in place.
- » Dedicated volunteer management team to advance the volunteer experience.
- » Board succession planning in place.

---

### 3. Failure to protect our planned fundraising growth from external economic factors:

The risk the Society will fail to grow its fundraising ambition as planned, and deliver the full ambition of its strategy.

#### Mitigation measures

- » Digital improvements and diversification.
- » Improve donor journey and engagement.
- » Build on brand recognition and brand strategy.
- » Consistent monitoring of the fundraising landscape.
- » Communicate our impact effectively.

---

### 4. Information security risk:

The risk of cybersecurity attack and data theft.

#### Mitigation measures

- » Strong induction and annual staff training in GDPR and IT security.
- » Development of cyber security policies.
- » Cross-organisational cyber security committee established.
- » Continual enhancement of our cyber security position.
- » Regular disaster recovery exercises conducted.

---

### 5. Failure to deliver strategic impact:

Failure to deliver our strategic goals, including expanding our reach and impact.

#### Mitigation measures

- » Strategic plan in place with annual reviews conducted, and linked to budgets.
- » Strong oversight by Board on Strategy plan.
- » Project management office in place.
- » Annual review of strategic landscape.
- » Mid-strategy review to be conducted in 2023.

The Board is satisfied that systems and processes are in place to monitor, manage and mitigate the Society's exposure to its major risks.





## Directors' responsibility statement

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- » select suitable accounting policies for the company financial statements and then apply them consistently;
- » make judgments and estimates that are reasonable and prudent;
- » state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- » prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that

the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

Approved by the Board and signed on its behalf by:

**Brid Horan**  
Director

**Allan Kearns**  
Director

**Date: May 4, 2023**

# OUR BOARD

Our Board of Directors strive to improve the lives of people affected by cancer.

We asked each of them the following question:

**What inspired you or motivated you to join the Board?**



## BRID HORAN, CHAIR

Brid is an independent non-executive Director experienced in executive roles and on public and private boards. Brid is currently Chancellor of Dublin City University and Governing Authority Chair, Chair of Nephin Energy, and a non-executive Director of PM Group. Brid retired as ESB Deputy Chief Executive in 2014. She has served on the boards of IDA Ireland, FBD Holdings plc and National Pensions Reserve Fund and as Co-Chair of Balance for Better Business. She is an Actuary, Chartered Director and Fellow IOD.

**Every year is difficult for those affected by cancer but recent years have been particularly challenging. The Irish Cancer Society continues to provide badly needed services and supports to patients, families and survivors, to advocate on their behalf and to invest in cancer research and clinical trials. The Board and I are indebted to our generous donors who make our work possible and to our dedicated staff and volunteers for their continuing passion and commitment.**



## PROFESSOR SINEAD BRENNAN

Sinead is a Radiation Oncologist in St. Luke's Hospital, Rathgar and in St. James's Hospital, Dublin. She is Director of Research at St. Luke's Radiation Oncology Network and St. Luke's Institute of Cancer Research. She is Chair of the Head and Neck DSSG at Cancer Trials Ireland, and Clinical Associate Professor at Trinity College Dublin. She is clinical lead of The Irish Research Radiation Oncology Group.


**In my role as a radiation oncologist I admire the Irish Cancer Society's work to support cancer patients and to create a better future for patients and their families.**



## PROFESSOR LIAM GROGAN

Liam is a Consultant Medical Oncologist in Beaumont Hospital and is an Honorary Clinical Associate Professor in the Royal College of Surgeons in Ireland.

**I became involved in the Society to support its independent voice and caring hand guiding cancer patients on their journey.**





## GER PENNY

Ger is a qualified accountant and Chartered Director, with more than 35 years' experience gained in operational, strategic and financial management positions in organisations in Ireland, the UK and Asia. He is CFO of the Sisk Group and also has extensive non-executive director experience from roles on listed and private businesses.

**// I have huge respect for the incredible work which the Society performs on a daily basis. The Society plays an important advocacy role to ensure that cancer care and prevention remain high on all stakeholders' agenda.**



## DR CORMAC G. KILTY PHD

Cormac is a biotech entrepreneur retired from executive functions; managing a biotech investment portfolio and involved with two angel investment groups in Ireland.

He was voted one of the top 100 influential Ireland-US business leaders by 'Business and Finance' in 2007 and 2008 and was awarded the US - Ireland Biolink award for contribution to Irish life sciences in 2007. Cormac is presently an Adjunct Professor of Medicine and Medicinal Chemistry at UCD, where he was also awarded Science Alumnus of the Year, 2020.

**// The Society's research funding is a major contributor in training our oncology researchers for Ireland.**



## IRENE O'GORMAN

Irene is a highly experienced Chief Marketing Officer, currently with EY Ireland. Prior to that she has held marketing director roles with KPMG in the Middle East, Deloitte in Ireland and has also worked with firms in South Africa and Australia.

**// It's a great honour to work with the Irish Cancer Society in support of a mutually shared vision, for a future without cancer.**



## ALEX WHITE

Alex White SC is a barrister and mediator. He is Director General of the Institute of International and European Affairs and a former government Minister and TD. Prior to commencing legal practice he was a programme producer with RTÉ.

**// There is huge admiration everywhere for the work and commitment of the Society's staff and volunteers. It is a real privilege to contribute to the Society as a Board member.**



## OUR BOARD CONTINUED



### ALLAN KEARNS

Allan Kearns is a senior manager in the Central Bank of Ireland with over 20 years' experience in economics, governance, analytics and risk management. He was previously Chair of the Asthma Society of Ireland Board.

**I am inspired by the broad cross-section of the Irish community drawn together by the Society with a common mission to transform for the better outcomes for patients with cancer. Equally, I am impressed at the high standards of governance the Society sets for itself.**



### DR MARY CANAVAN

Dr Mary Canavan obtained her PhD in Immunology in 2012 and is now an Assistant Professor in Immunology in Trinity College Dublin. Her research group focuses on the immunological mechanisms that drive Rheumatological diseases. Mary is an Irish Cancer Society Advocacy Champion and PPI reviewer and has spoken publicly about being diagnosed with breast cancer when she was nine weeks pregnant with her first baby.


**Having suffered from breast cancer myself, I have seen first-hand the difficulties families face after a cancer diagnosis and how vital the Society's support services can be. I joined the Board so I could use this patient experience to help achieve the Society's vision – that by 2025, 3 out of 4 patients will survive their diagnosis.**




### MARIA FLEMING

Maria Fleming is CEO of First Fortnight, Ireland's mental health arts festival. Maria has over 20 years' experience working as a general manager, producer, programmer and arts consultant with Ireland's leading companies, including Dublin Theatre Festival, The Ark, Druid Theatre Company and Irish Modern Dance Theatre. Maria is passionate about social justice. In addition, Maria volunteers as an Advocacy Champion for the Irish Cancer Society.

**I am proud of the work the Irish Cancer Society do. One recent example is the success they achieved in abolishing day charges in hospitals which is of huge assistance to cancer patients and their families.**



IRISH CANCER SOCIETY  
ORGANISATION CHART 2023





Participants and volunteers at the Moylagh JFK 50 Mile Challenge, in aid of The Irish Cancer Society, LARCC and Palliative Care.





# FINANCIAL STATEMENTS

Independent auditor's report	74
Statement of financial activities	77
Balance sheet	78
Statement of cash flows	79
Notes to the financial statements	80
Reference and administrative details	102



# Independent auditor's report to the Members of Irish Cancer Society

---

## Report on the audit of the financial statements

### Opinion on the financial statements of Irish Cancer Society ("the company")

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2022 and of the loss for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Profit and Loss Account;
- the Statement of Comprehensive Income;
- the Balance Sheet;
- the Statement of Changes in Equity;
- the Cash Flow Statement; and
- the related notes 1 to 27, including a summary of significant accounting policies as set out in note 1.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council ("the relevant financial reporting framework").

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

# Independent auditor's report to the Members of Irish Cancer Society (continued)

---

## Other information

The other information comprises the information included in the Annual Report and Audited Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Report and Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on IAASA's website at: <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements>. This description forms part of our auditor's report.



# Independent auditor's report to the Members of Irish Cancer Society (continued)

---

## Report on other legal and regulatory requirements

### Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

### Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

### Use of our report

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### Emer O'Shaughnessy

For and on behalf of Deloitte Ireland LLP Chartered Accountants and Statutory Audit Firm  
Deloitte & Touche House, 29 Earlsfort Terrace,  
Dublin 2

Date: 12 May, 2023

# Statement of financial activities

	Notes	2022 Unrestricted	2022 Restricted	2022 Designated	2022 Total	2021 Unrestricted	2021 Restricted	2021 Designated	2021 Total
		€'000	€'000	€'000	€'000	€'000	€'000	€'000	€'000
<b>INCOME:</b>									
Donations and legacies	3(a)	15,883	3,926	-	19,809	18,773	3,241	-	22,014
Trading activities	3(b)	4,155	-	-	4,155	2,534	-	-	2,534
Investments	3(c)	122	-	-	122	106	-	-	106
Charitable activities	3(d)	1,022	1,425	-	2,447	964	700	-	1,664
Other income	3(e)	86	-	-	86	269	-	-	269
<b>Total income</b>		<b>21,268</b>	<b>5,351</b>	<b>-</b>	<b>26,619</b>	22,646	3,941	-	26,587
<b>EXPENDITURE:</b>									
Charitable activities	4	13,388	4,870	-	18,258	12,024	4,004	-	16,028
Fundraising activities	5	5,723	-	-	5,723	4,757	14	-	4,771
Trading activities		3,099	-	-	3,099	2,256	-	-	2,256
<b>Total expenditure</b>		<b>22,210</b>	<b>4,870</b>	<b>-</b>	<b>27,080</b>	19,037	4,018	-	23,055
Net (loss)/gain on investments	13	(1,537)	-	-	(1,537)	891	-	-	891
<b>Net (deficit)/income</b>	9	<b>(2,479)</b>	<b>481</b>	<b>-</b>	<b>(1,998)</b>	4,500	(77)	-	4,423
Taxation	10	-	-	-	-	-	-	-	-
Transfers between funds	8	-	-	-	-	-	-	-	-
<b>Net movement in funds</b>		<b>(2,479)</b>	<b>481</b>	<b>-</b>	<b>(1,998)</b>	4,500	(77)	-	4,423
<b>RECONCILIATION OF FUNDS:</b>									
Funds balances brought forward		32,442	413	1,000	33,855	27,942	490	1,000	29,432
<b>Funds balances carried forward</b>		<b>29,963</b>	<b>894</b>	<b>1,000</b>	<b>31,857</b>	32,442	413	1,000	33,855

There are no other recognised gains or losses for the financial year except for those listed above. All income and expenditure derives from continuing operations.

# Balance sheet

	Notes	2022 €'000	2021 €'000
<b>Fixed assets</b>			
Tangible assets	12	8,567	8,824
<b>Total fixed assets</b>		<b>8,567</b>	8,824
<b>Current assets</b>			
Investments	13	6,664	8,142
Stocks		193	256
Debtors: Amounts falling due within one year	14	1,935	1,348
Cash at bank and in hand		22,743	22,389
<b>Total current assets</b>		<b>31,535</b>	32,135
<b>Creditors: Amounts falling due within one year</b>	15	<b>(5,956)</b>	(3,946)
<b>Net current assets</b>		<b>25,578</b>	28,189
<b>Total assets less current liabilities</b>		<b>34,146</b>	37,013
<b>Creditors: Amounts falling due after more than one year</b>			
Long term liabilities	15	(2,289)	(3,158)
<b>NET ASSETS</b>		<b>31,857</b>	33,855
<b>Funds:</b>			
Restricted income funds	8	894	413
<u>Unrestricted income funds</u>			
General income funds		29,963	32,442
Designated income funds		1,000	1,000
Total unrestricted income funds		30,963	33,442
<b>TOTAL FUNDS</b>		<b>31,857</b>	33,855

The financial statements were approved and authorised for issue by the Board of Directors and signed May 4, 2023 on its behalf by:



Brid Horan  
Director



Allan Kearns  
Director



# Statement of cash flows

---

	Notes	2022 €'000	2021 €'000
Cash flows from operating activities:			
<b>Net cash generated by operating activities</b>	18	<b>(913)</b>	6,666
Cash flows from investing activities:			
Purchase of fixed assets	12	<b>(211)</b>	(130)
<b>Net cash flow from investing activities</b>		<b>(211)</b>	(130)
<b>Decrease in cash and cash equivalents</b>		<b>(1,124)</b>	6,536
Cash and cash equivalents at 1 January		<b>30,531</b>	23,995
Cash and cash equivalents at 31 December		<b>29,407</b>	30,531
Analysis of cash and cash equivalents			
Bank and cash		<b>22,743</b>	22,389
Cash equivalents		<b>6,664</b>	8,142
Cash and cash equivalents at 31 December		<b>29,407</b>	30,531

# Notes to the financial statements

---

## 1. Accounting policies

### General information

The purpose of the Irish Cancer Society is to improve the lives of those affected by cancer.

Irish Cancer Society is a not-for-profit company limited by guarantee with a charitable status. It is incorporated in the Republic of Ireland, with registration number of 20868. The address of its registered office is 43/45 Northumberland Road, Dublin 4. The Society is a public benefit entity.

### Statement of compliance

The financial statements of the Society for the year ended 31 December 2022 have been prepared in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the FRS 102 (Charities SORP – FRS 102), and in accordance with the Irish statute comprising the Companies Act 2014.

### Basis of preparation

The financial statements have been prepared on a going concern basis, under the historical cost convention, modified to include the revaluation of investments to fair value. The financial statements have been prepared in accordance with FRS102, and in accordance with the Statement of Recommended Practice, as applicable to charities preparing their accounts in accordance with FRS102 (issued by the Charity Commission for England and Wales, the Charity Commission for Northern Ireland and the Office of the Scottish Charity Regulator "the Charities SORP"). The presentation and functional currency of these financial statements is euro.

### Going concern

The financial statements have been prepared on a going concern basis. The Directors have reviewed the 2022 Statement of Financial Activities and Balance Sheet, the approved 2023 budget and the latest financial information. The Directors are satisfied that the Society has adequate resources to continue in operational existence for the next 12 months, and as a result are satisfied that there are sufficient resources to manage any operational or financial risks. There is no material uncertainty that affects this assumption.

## INCOME

Income is analysed in the Statement of Financial Activities under the following headings:

- Donations and legacies
- Trading activities
- Investments
- Charitable activities
- Other income

Income is recognised when the Society becomes entitled to the funds, receipt is probable and the amount can be quantified with reasonable accuracy.

Where income has not yet been received, but all criteria for recognition have been satisfied, the income is accrued as a debtor on the Balance Sheet. Where income has been received in advance, it is deferred as a creditor on the Balance Sheet until income recognition conditions are met.

Income arising from tax rebates is recognised on confirmation from the tax authorities of the amount and when there is certainty of receipt.

Grant income is recognised as income when the entitlement to the income has been met, and the Society is legally entitled to the income. Grant income is recognised as income in the year to which it relates.

### Donations and legacies

Donations are recognised when received, or when all criteria for recognition have been satisfied.

Income arising from legacies is recognised when it becomes probable that funds will be received; i.e. where there is a grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached are within the control of the Society.

Donations-in-kind are recognised as income when received. Donations-in-kind are valued at open market value or at a reasonable estimate of the gross value to the Society.

### Trading activities

Income from trading activities includes retail income from the sale of donated goods through shops, and income related to the sale of Christmas cards.

# Notes to the financial statements (continued)

## 1. Accounting policies (continued)

Goods donated for resale are accounted for when they are sold rather than when they are donated because the high volume of low value items makes valuation impractical.

### Investments

Investment income includes interest, dividends, and other income related to the Society's investment portfolio.

### Charitable activities

#### Grant income

Grant income from government agencies and other entities relating to the Society's charitable activities is recognised as income when the entitlement to the income has been met, and the Society is legally entitled to the income. Grant income is recognised as income in the year to which it relates.

#### Charitable activities reimbursements

Charitable activities reimbursements relate to the provision of nursing services by the Society to other charities and healthcare organisations. The reimbursements are recognised as income when receivable.

#### Other income

Includes income that is not directly attributable to the Society's charitable activities. Other income is recognised when an entitlement to receipt has been met.

### EXPENDITURE

Expenditure is analysed between charitable activities, fundraising activities and trading activities. The costs of each activity are separately disclosed and analysed according to their major components.

Expenditure is recognised when a legal or constructive obligation exists as a result of a past event, a transfer of economic benefits is required in settlement and the amount of the obligation can be reliably measured.

Support costs, which cannot be attributed directly to one activity, are allocated to activities on a headcount basis.

Governance costs, which are included within support costs, consist of direct expenditure and overhead costs incurred in relation to the strategic, as opposed to day-to-day management of the charity, and in relation to compliance with constitutional and statutory requirements. Costs related to audit and organisational risk management are also included in this category.

Redundancy and termination payments are recognised when there is a demonstrable commitment that cannot be realistically withdrawn.

### Charitable activities

Costs of charitable activities include costs of cancer awareness and prevention programmes and publications, services and support to improve the lives of cancer patients and survivors, collaborative research programmes and advocacy work, together with related support costs. All costs of charitable activities are recognised on an accruals basis.

Research and services grant costs are recognised in full in the year in which the commitment is made where there is an expectation that the full amount committed will be fully expended. When this is not certain, the costs are recognised over the term of the contract. Research and services grants are paid over the term of the grant agreement, and the outstanding balances at year-end are held under creditors on the Balance Sheet and split between current and long-term liabilities.

Expenditure in the form of grants to local partners is recognised on an accrual basis.

### Fundraising activities

Fundraising activities comprise expenditure incurred on fundraising, including the costs of advertising, producing publications, printing and mailing fundraising material, staff costs and an appropriate allocation of support costs. All fundraising activities costs are recognised on an accruals basis.

### Trading activities

Trading activities comprise expenditure incurred in relation to the Society's network of 21 charity shops. All trading activities costs are recognised on an accruals basis.



# Notes to the financial statements (continued)

## 1. Accounting policies (continued)

### LEASES

Leases where substantially all the benefits and risks of ownership remain with the lessor are classified as operating leases. Payments made under operating leases are charged to the income statement on an accruals basis.

### FUND ACCOUNTING

The Society maintains the following funds.

#### Restricted funds

Represent income that can only be used for a particular charitable purpose. Such restrictions are imposed by the donor or by the nature of the fundraising appeal.

#### Unrestricted funds

##### *Unrestricted funds - general*

Represent income that can be used by the Society without restrictions. These funds are available to spend at the discretion of the Society in furtherance of its charitable objectives.

##### *Unrestricted funds - designated*

These are unrestricted funds set aside at the discretion of the Directors for specific purposes. Any transfers to and from designated funds are approved by the Directors.

### TANGIBLE FIXED ASSETS

Tangible assets are recognised when a resource is controlled by the Society as a result of a past event or transaction, it is probable that the expected future economic benefits associated with the asset will flow to the Society, and the historical or fair value can be reliably measured.

Tangible fixed assets are stated at cost less accumulated depreciation, and the carrying values are reviewed annually for impairment. Depreciation is provided for on all tangible fixed assets at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Freehold premises	2.0% per annum
Fixtures and fittings	10.0% per annum
Motor vehicles	25.0% per annum
Furniture and equipment	20.0% per annum
Computer equipment/software	33.3% per annum

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

### INVESTMENTS

A listed investment is a financial instrument that is traded on an exchange. Listed investments are included on the Balance Sheet at fair value, at their closing bid price, or mid-price, or last traded price.

An unlisted investment is a financial instrument that is not traded on an exchange. Unlisted investments are included on the Balance Sheet at their fair value. For unlisted funds this is based on the Society's share of the net asset value of the investments using the latest available performance data.

Investments are classified as current assets on the Balance Sheet as they can be converted to cash within three months.

Cash which is held by the Society's investment advisors, and managed by them in accordance with the Society's mandate, is classified as a current asset on the Balance Sheet under investments.

Realised gains and losses on disposals in the year and unrealised gains and losses on investments at the Balance Sheet date are included in the Statement of Financial Activities for the relevant underlying funds.

All investment income is treated as unrestricted.

### STOCK

Goods purchased for resale are stated at the lower of cost and estimated selling price less costs to complete and sell, which is equivalent to the net realisable value. Cost is defined as invoice price.

Unsold donated items are not included in closing stock since their cost is nil and their value is difficult to ascertain until sold.

### ASSETS HELD FOR SALE

Gifted properties awaiting sale are valued at their fair value, which is their expected sale price less costs of sale and are valued by an independent valuer who holds a relevant professional qualification and has relevant experience of both the class and location of the asset.

# Notes to the financial statements (continued)

## 1. Accounting policies (continued)

### CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash in hand, and deposits with banks requiring less than three months' notice of withdrawal.

### FINANCIAL INSTRUMENTS

Financial assets and financial liabilities are recognised when the Society becomes a party to the contractual provisions of the instrument. Financial liabilities are classified according to the substance of the contractual arrangements entered into.

Financial instruments are recognised and measured in accordance with Section 11 of FRS 102.

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Society intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

### Trade and other debtors

Trade and other debtors are recognised at the settlement amount due after any discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

### Trade and other creditors

Creditors and provisions are recognised where the Society has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be reliably measured or estimated. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due and at their present value where the time value of money is deemed significant.

### RETIREMENT BENEFITS

The Irish Cancer Society operates a defined contribution ("DC") pension scheme. Contributions payable to this scheme are charged to the Statement of Financial Activities in the period to which they relate. Amounts not yet remitted at the year-end are included in accruals on the Balance Sheet. The assets of the plan are held separately from the Society in independently administered funds.

### TAXATION

The Society has been granted an exemption under Sections 207 and 208 of the Taxes Consolidation Act 1997.

## 2. Critical accounting judgements and key sources of estimation uncertainty

In the application of the Society's accounting policies, which are described in Note 1, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The Directors do not consider there are any critical judgements or sources of estimation uncertainty in the application of the accounting policies in Note 1.

## Notes to the financial statements (continued)

### 3. Income

a) Donations and legacies	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
Daffodil Day	4,602	98	4,700	7,863
Other national campaigns & donations	3,809	1,651	5,460	6,362
<b>Total national campaigns &amp; donations</b>	<b>8,411</b>	<b>1,749</b>	<b>10,160</b>	14,225
Individual giving	2,987	222	3,209	3,056
Philanthropy & corporate partnerships	2,072	1,914	3,986	2,431
<b>Total donations</b>	<b>13,470</b>	<b>3,885</b>	<b>17,355</b>	19,712
Legacies	2,413	41	2,454	2,302
<b>Total</b>	<b>15,883</b>	<b>3,926</b>	<b>19,809</b>	22,014

Other national campaigns and donations income comprises income from community, social media, and Society led national campaigns, and general donations.

Individual giving income includes regular giving income and special appeal donations.

b) Trading activities	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
Shop income	4,142	-	4,142	2,521
Other trading activities	13	-	13	13
<b>Total</b>	<b>4,155</b>	<b>-</b>	<b>4,155</b>	2,534
c) Investments	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
Investment income	122	-	122	106
<b>Total</b>	<b>122</b>	<b>-</b>	<b>122</b>	106



## Notes to the financial statements (continued)

### 3. Income (continued)

d) Income from charitable activities	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
Dept. of Health - HSE – Travel2Care – NCCP – annual funding	-	350	350	350
Dept. of Health - HSE – Night Nursing - National Palliative Care Programme – annual funding	-	350	350	350
Dept. of Health - HSE – Night Nursing - National Palliative Care Programme – winter funding	-	550	550	-
Dept. of Health - HSE – Night Nursing - National Palliative Care Programme – once-off funding	-	175	175	-
Government grants relating to charitable activities	-	1,425	1,425	700
Night nursing reimbursements	1,004	-	1,004	947
Other	18	-	18	17
<b>Total</b>	<b>1,022</b>	<b>1,425</b>	<b>2,447</b>	<b>1,664</b>

Night nursing reimbursements relate to the provision of night nursing palliative care services by the Society to various hospices and medical centres and to the Irish Hospice Foundation.

Department of Health HSE Grant income	Travel2Care €'000	Night Nursing €'000
Restricted income carried forward	325	-
Current year income	350	1,075
Carried forward income offset against expenditure	(325)	-
Current year income offset against expenditure	(50)	(1,075)
Restricted income to be carried forward	300	-
Current year income received in current year	-	925
Current year income receivable at 31 December 2022	350	150
<b>Current year income</b>	<b>350</b>	<b>1,075</b>

e) Other income	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
VAT Compensation Scheme	86	-	86	56
COVID-19 Government subsidies and grants	-	-	-	109
Other	-	-	-	104
<b>Total</b>	<b>86</b>	<b>-</b>	<b>86</b>	<b>269</b>

## Notes to the financial statements (continued)

### 4. Analysis of expenditure on charitable activities

The table below analyses direct, operating and support costs. Direct costs are the delivery costs of an activity including direct salaries. Operating costs are other direct costs related to a particular charitable activity goal. Support costs are analysed in Note 6.

	2022 Heathy living €'000	2022 Catching cancer early €'000	2022 Treating cancer €'000	2022 Living well €'000	2022 End of life care €'000	2022 Total €'000
<b>Services and advocacy</b>						
Public and patient awareness and education campaigns	395	395	216	338	116	1,460
Cancer Support Centre Funding*	-	-	501	501	-	1,002
Volunteer drivers	-	-	787	-	-	787
Travel2Care (NCCP)	-	-	-	382	-	382
Financial support	-	-	-	619	-	619
Patient Education Programme	-	-	202	-	-	202
Community & Survivorship	-	-	-	396	-	396
CAYA	-	-	-	398	-	398
Night nursing	-	-	-	-	3,726	3,726
Daffodil centres*	29	81	437	468	38	1,053
Support line*	9	25	255	147	12	448
Programme management	38	38	38	38	38	190
Advocacy	38	118	100	122	38	415
Operating costs	32	41	152	171	139	535
<b>Total direct and operating costs</b>	<b>542</b>	<b>699</b>	<b>2,688</b>	<b>3,580</b>	<b>4,106</b>	<b>11,613</b>
Support costs	138	178	648	710	543	2,217
<b>Total services and advocacy</b>	<b>679</b>	<b>876</b>	<b>3,336</b>	<b>4,292</b>	<b>4,649</b>	<b>13,830</b>
<b>Research</b>						
Translational	-	2	810	-	-	812
Survivorship	-	2	2	1,122	86	1,213
Trials	-	-	1,080	-	-	1,080
Other strategic	-	-	296	282	-	577
Operating costs	-	0	332	188	11	532
<b>Total direct and operating costs</b>	<b>-</b>	<b>4</b>	<b>2,520</b>	<b>1,592</b>	<b>97</b>	<b>4,213</b>
Support costs	-	0	134	76	5	215
<b>Total research</b>	<b>-</b>	<b>4</b>	<b>2,654</b>	<b>1,668</b>	<b>102</b>	<b>4,428</b>
<b>Total charitable activities</b>	<b>679</b>	<b>881</b>	<b>5,989</b>	<b>5,957</b>	<b>4,752</b>	<b>18,258</b>

* These activities are included under the strategic priority "Treating Cancer" in the Strategic Review section, for ease of discussion. The relevant costs are allocated across a number of strategic priorities in table above.



## Notes to the financial statements (continued)

### 5. Fundraising activities

Costs comprise the following:

	2022 Unrestricted €'000	2022 Restricted €'000	2022 Total €'000	2021 Total €'000
Daffodil Day	967	-	967	871
Other national campaigns and donations	430	-	430	318
<b>Total national campaigns and donations</b>	<b>1,397</b>	<b>-</b>	<b>1,397</b>	<b>1,189</b>
Individual giving	949	-	949	574
Philanthropy and corporate partnerships	50	-	50	60
<b>Total donations</b>	<b>2,395</b>	<b>-</b>	<b>2,395</b>	<b>1,823</b>
Legacies	10	-	10	15
<b>Donations and Legacies costs</b>	<b>2,405</b>	<b>-</b>	<b>2,405</b>	<b>1,838</b>
Operating costs	2,110	-	2,110	1,866
<b>Total direct costs</b>	<b>4,516</b>	<b>-</b>	<b>4,516</b>	<b>3,704</b>
Investment management costs	63	-	63	65
Support costs (Note 6)	1,144	-	1,144	1,002
<b>Total</b>	<b>5,723</b>	<b>-</b>	<b>5,723</b>	<b>4,771</b>



## Notes to the financial statements (continued)

### 6. Support costs

Support costs are the costs of personnel and associated technology, finance, human resources and other central functions. Also included are the governance costs comprising the external annual audit and other legal and regulatory compliance.

Support costs are allocated across the Society's activities to fairly represent the cost of delivering those activities. The costs have been allocated on a headcount basis and are apportioned as follows:

- 62% (2021: 59%) to Services and Advocacy
- 32% (2021: 34%) to Fundraising
- 6% (2021: 7%) to Research

	2022 Services and Advocacy €'000	2022 Research €'000	2022 Fundraising €'000	2022 Total €'000	2021 Total €'000
Information Technology	858	83	443	1,384	1,092
Finance	431	42	223	696	630
Human Resources	344	33	177	554	361
Other	583	56	301	941	865
<b>Total</b>	<b>2,217</b>	<b>215</b>	<b>1,144</b>	<b>3,576</b>	<b>2,948</b>

Other costs include facilities, utilities and CEO office costs to fund support networks to cancer survivors, providing patient transport through our Volunteer Driver Service, peer-to-peer educational programmes, funding counselling for survivors (remote and through our partner cancer support centres) and our annual conferences.

Included in the support costs are the following governance costs:

	2022 €'000	2021 €'000
Legal and professional fees	27	7
Audit fees	35	31
<b>Total</b>	<b>62</b>	<b>38</b>

## Notes to the financial statements (continued)

### 7. Research Grants

Expenditure on the following grants was charged in 2022:

Recipient	Project description	€'000
Cancer Trials Ireland	Strategic funding for 2022	1,000
University College Cork	Men's Health Initiative	300
Dr Petra Jaguš	RCSI, University of Medicine and Health Sciences for the translational research fellowship "Characterising the role of RET in facilitating cancer spread to the brain"	240
Prof Roisin Connolly & Prof Josephine Hegarty	University College Cork Women's Health Initiative Two 2 Year Extension (Breast Cancer)	200
Prof Donal Brennan	University College Dublin Womens Health Initiative (Gynaecological Oncology)	200
Dr Grainne O'Kane	Trinity St James Cancer Institute (TSJCI) Clinician Research Leadership Award	199
Anastasija Walsh	Translational PhD Scholarship awarded to University of Galway entitled "Investigating the role of extracellular vesicle sialic acids in colorectal cancer tumour derived immunosuppression"	160
Megan McAuley	Translational PhD Scholarship awarded to Trinity College Dublin entitled "Turning up the Voltage on Anti-Cancer Immunity"	159
Prof Aoife Lowery	University of Galway: Women's Cancer Survivorship 2022	150
Dr Catriona Dowling	HRCI-HRB JOINT FUNDING SCHEME 2022 Awarded to University of Limerick entitled "Combining HDAC6 inhibitors with KRAS inhibitors for the treatment of Non-Small Cell Lung Cancer (NSCLC)"	150
Conor Hussey	Social, Nursing & Allied Health (SNAH) PhD Scholarship awarded to University of Galway	136
Dr Jessie Elliott	Trinity College Dublin : Clinician Research Development Fellowship	120
Prof Maeve Lowery	Trinity St James Cancer Institute (TSJCI) Public and Patient Partnership Lead Award	104
Dr Blaithin Moriarty	Oncodermatology Fellowship	104
Leah Schafer	Translational PhD on Poor Prognosis Cancers awarded to University College Dublin	86
Prof Janusz Krawczyk	Clinical Trials Catalyst Award to University of Galway	80
Dr Gráinne Sheill	Allied Health Professional Leadership Award to Trinity College Dublin	75
Dr Naomi Algeo	Allied Health Professional Leadership Award to Trinity College Dublin	74
Dr Mary Nevin	Palliative Care Award to Dublin City University	50
Prof Suzanne Guerin	Improved Support for Underrepresented Communities awarded to University College Dublin	48
Dr Suzanne Denieffe	Palliative Care Award to South East Technological University	36
Various	Various research projects and grants, including support of IARC conference and student grants.	97

## Notes to the financial statements (continued)

Recipient	Project description	€'000
Various	Prior years research grants unused / cancelled and returned	(87)
Operating Costs	Management of tenders, review and oversight	532
Total direct costs		4,213
Support and central costs	(Note 4)	215
<b>Total</b>		<b>4,428</b>

The summary above includes the commitments entered into and recognised in 2022. Grant recipients typically receive payments over the period of the grant which is determined by the conditions of the underlying agreement. During the year 139 researchers worked on research projects funded by the Society (2021: 129).

The process for guiding the nature of research grants is overseen by the Research Advisory Committee. Typically the Society issues a grant call for a particular subject area and sets the selection criteria. The Society then appoints an independent panel of experts and patient representatives to adjudicate the submissions based on the Society's selection criteria. Grant recipients are required to send progress reports to the Society at set milestones, and the payment of instalments is dependent on the receipt of satisfactory progress reports. The results of research projects funded by the Society are typically published in reputable research or medical journals and the Society's contribution is noted therein. Research may also be used to inform developments in health system and practice, for example outlining hurdles to accessing care or improving outcome.

### 8. Analysis of charitable funds

#### A) Analysis of movement in designated unrestricted funds

The designated fund comprises amounts allocated by the Directors from general unrestricted income.

The €1.0m fund relating to research is held to protect currently committed research programmes from future unexpected variations in income. The time horizon on research programmes is typically three to five years.

	Opening balance as at	Income/ expenditure	Transfers	Closing balance as at
	01/01/2022 €'000	2022 €'000	2022 €'000	31/12/2022 €'000
Research	1,000	-	-	1,000

## Notes to the financial statements (continued)

### 8. Analysis of charitable funds (continued)

#### b) Analysis of Movement in Restricted Funds

Restricted funds are funds received where the donor has specified how the funds are to be used.

	Opening balance as at 01/01/2022 €'000	Income 2022 €'000	Expenditure 2022 €'000	Transfers 2022 €'000	Closing balance as at 31/12/2022 €'000
Breast cancer	-	853	(853)	-	-
Prostate cancer	-	115	(115)	-	-
Travel2Care grants (State)	323	350	(375)	-	300
Research	53	1,089	(1,142)	-	-
Nursing*	-	1,768	(1,768)	-	-
Paediatric cancer	-	3	(3)	-	-
Survivorship	15	100	(115)	-	-
Reduce the risk	-	73	(73)	-	-
Cancer Information Services	22	-	(22)	-	-
Children, Adolescents and Young Adults	-	1,000	(405)	-	595
<b>Total</b>	<b>413</b>	<b>5,351</b>	<b>(4,870)</b>	<b>-</b>	<b>894</b>

**Breast cancer:** to fund information, advice, research and support services for women and men affected by breast cancer.

**Prostate cancer:** to fund information, advice, research and support services for men affected by prostate cancer.

**Travel2Care:** to fund financial assistance for patients who travel to hospital appointments.

**Research:** to fund vital cancer research programmes to deliver new hope and supports for patients, enabling new therapies, and building an advanced cancer research infrastructure which will enhance the country's cancer care capabilities into the future.

**Nursing:** to fund support to patients who need end-of-life care through a home nursing service and to fund advice and guidance through our Cancer Nurseline and Daffodil Centres.

**Paediatric cancer:** to fund research and support services (including financial support) for children affected by cancer.

**Survivorship:** to fund support networks to cancer survivors, providing patient transport through our Volunteer Driver Service, peer-to-peer educational programmes, funding counselling for survivors (remote and through our partner cancer support centres) and our annual conferences.

**Reduce the Risk:** To fund programmes aimed at raising awareness and sharing information on how to avoid cancer.

**Cancer Information Services:** to fund the provision of the Society's online platform in order to enhance the Society's ability to disseminate cancer related information.

**Children, Adolescents and Young Adults:** to fund research and support services for children and young adults affected by cancer.

*This income includes €1,075,000 of HSE grant funding for the Society's night nursing service.



## Notes to the financial statements (continued)

### 8. Analysis of charitable funds (continued)

#### c) Analysis of movement in unrestricted funds

Unrestricted funds are funds received where the donor has not specified how the funds are to be used.

	Opening balance as at 01/01/2022 €'000	Income 2022 €'000	Expenditure 2022 €'000	Transfers 2022 €'000	Losses 2022 €'000	Closing balance as at 31/12/2022 €'000
General fund	32,442	21,268	(22,210)	-	(1,537)	29,961

#### d) Analysis of net assets between funds

	Restricted funds €'000	Designated unrestricted funds €'000	General unrestricted funds €'000	Total 2022 €'000
Tangible fixed assets	-	-	8,567	8,567
Current assets	894	1,000	29,641	31,535
Current and long-term liabilities	-	-	(8,245)	(8,245)
<b>Total</b>	<b>886</b>	<b>1,000</b>	<b>29,963</b>	<b>31,857</b>

In respect of prior year:

	Restricted funds €'000	Designated unrestricted funds €'000	General unrestricted funds €'000	Total 2021 €'000
Tangible fixed assets	-	-	8,824	8,824
Current assets	413	1,000	30,722	32,135
Current and long-term liabilities	-	-	(7,104)	(7,104)
<b>Total</b>	<b>413</b>	<b>1,000</b>	<b>32,442</b>	<b>33,854</b>

# Notes to the financial statements (continued)

## 9. Net income for the financial year (continued)

	2022 €'000	2021 €'000
This is stated after charging:		
Depreciation	461	441
Auditor's remuneration:		
Audit of financial statements	35	31
Other assurance services	5	5
Tax advisory services	-	3
Other non- audit services	-	31
Directors' remuneration	-	-
Profit on sale of fixed assets	7	-
Operating lease charge	696	685

The Directors all serve in a voluntary capacity and do not receive any remuneration.

## 10. Taxation

No charge to corporation taxation arises as the Society has been granted exemption under Sections 207 and 208 of the Taxes Consolidation Act 1997.

## 11. Employees and remuneration

The Society employs staff to deliver on its strategy, raise income and provide infrastructure and support. Staff costs are allocated to the following activities: charitable activities, fundraising, charity shops and support.

The average number of persons (on a full-time equivalent basis) employed by the Society during the financial year is set out below:

	2022 Number	2021 Number
Charitable activities	70	55
Charitable activities – night nursing	43	46
Fundraising	32	29
Charity shops	44	30
Support	35	31
	224	191

### Night Nursing

The Society employs Night Nurses to provide free end-of-life care in patients' homes. In 2022 211 (2021: 207) nurses were employed for at least one night by the Society with an average of 87 nurses working each week (2021: 89). This equates to 43 (2021: 46) nurses on a full-time equivalent basis.

# Notes to the financial statements (continued)

## 11. Employees and remuneration (continued)

The aggregate payroll costs were as follows:

	2022 €'000	2021 €'000
Salaries	11,642	9,708
Social welfare costs	1,202	1,011
DC pension scheme employer contributions (Note 20)	573	463
Permanent health, life assurance and DC pension scheme costs	168	169
<b>Total</b>	<b>13,585</b>	<b>11,351</b>

In 2022 there were redundancy costs of €94,184 in relation to two people (2021: no redundancy costs).

Employee remuneration (excluding pension, redundancy and end-of-contract holiday pay) of €60,000 and over:

	2022 Number	2021 Number
€60,000 - €70,000	16	11
€70,001 - €80,000	2	6
€80,001 - €90,000	6	1
€90,001 - €100,000	3	4
€100,001 - €110,000	-	1
€110,001 - €120,000	-	1
€120,001 - €130,000	-	-
€130,001 - €140,000	-	-
€140,001 - €150,000	1	1
> €150,001	-	-

Key management personnel is defined as the CEO and the members of the executive leadership team. The total emoluments (including benefits, pension and redundancy) paid to key management personnel in 2022 was €854,138 (2021: €726,341).

In 2022 the CEO was paid a salary of €137,020 (2021: €131,349 and a travel allowance of €10,000 (2021: €10,000)). The Society contributed 20% (2021: 20%) of the CEO's salary to the defined contribution pension scheme.

### Director expenses

Directors receive no remuneration for their services. Out-of-pocket expenses incurred in connection with their duties may be claimed. In 2022 the Society made payments of €Nil (2021: €Nil) in relation to out-of-pocket expenses.

## Notes to the financial statements (continued)

### 12. Tangible assets

	Freehold premises	Computer fixtures & fittings	Motor vehicles	Furniture & equipment	Equipment & software	Total
	€'000	€'000	€'000	€'000	€'000	€'000
<b>Cost:</b>						
At 01/01/2022	13,283	259	19	585	1,572	15,718
Additions	-	13	36	57	105	211
Disposals	-	-	(19)	(256)	(362)	(637)
<b>At 31/12/2022</b>	<b>13,283</b>	<b>272</b>	<b>36</b>	<b>386</b>	<b>1,315</b>	<b>15,292</b>
<b>Depreciation:</b>						
At 01/01/2022	4,727	180	19	529	1,439	6,894
Charge for financial year	265	13	9	39	135	461
Disposals	-	-	(19)	(249)	(362)	(630)
<b>At 31/12/2022</b>	<b>4,992</b>	<b>193</b>	<b>9</b>	<b>319</b>	<b>1,212</b>	<b>6,725</b>
<b>Net book amounts:</b>						
<b>At 31/12/2022</b>	<b>8,291</b>	<b>79</b>	<b>27</b>	<b>67</b>	<b>103</b>	<b>8,567</b>

Net book amounts:

At 31/12/2021	8,556	79	-	56	133	8,824
---------------	-------	----	---	----	-----	-------

Included in freehold premises is a property that is used for trading activities; a section of this property that is currently surplus to operational requirements, is rented to a third party on a short-term commercial basis. The rental income from this property in 2022 was €13,000 (2021: €13,000) and is included under other trading activities in Note 3. The other 20 shops are held on a leasehold basis.

### 13. Current asset investments

	2022 €'000	2021 €'000
At 1 January	8,142	7,210
(Loss)/gain on investments	(1,537)	891
Investment income	122	106
Management fees	(63)	(65)
<b>At 31 December</b>	<b>6,664</b>	<b>8,142</b>



## Notes to the financial statements (continued)

### 13. Current asset investments (continued)

The funds are held in the following classes of investments:

	2022 €'000	2021 €'000
Cash and cash equivalents	380	243
Listed investments	6,132	7,737
Other investments	152	162
<b>Total</b>	<b>6,664</b>	<b>8,142</b>

	2022 €	2021 €
Investment in Subsidiary (Note 23):		
At 1 January	1	1
Impairment loss	-	-
At 31 December	1	1

The Irish Cancer Society has a 100% investment in a subsidiary undertaking called Irish Cancer Society Research Limited.

The directors believe the carrying value of the investments is supported by its underlying net assets. The net assets of Irish Cancer Society Research Limited were €3 in 2022 (2021: €3).

Investment funds are included in the accounts at fair value and any fluctuations are accounted for in the Statement of Financial Activities.

### 14. Debtors:

#### Amounts falling due within one year

	2022 €'000	2021 €'000
Trade and other debtors	700	326
Accrued income	766	575
221+ support group balance due	-	1
Prepayments	469	446
<b>Total</b>	<b>1,935</b>	<b>1,348</b>

All trade debtors are due within the Society's normal terms, which is typically 30 days.

## Notes to the financial statements (continued)

### 15. Creditors

Amounts falling due within one year:

	2022 €'000	2021 €'000
Trade and other creditors	713	489
Accruals	646	532
221+ support group funds held in trust	14	-
Payroll taxes	330	286
Instalments due on research and services grants payable	4,253	2,639
<b>Total</b>	<b>5,956</b>	<b>3,946</b>

The repayment terms of trade creditors vary between on demand and 90 days.

The 221+ support group balance due relates to funds due to 221+CCG Cervical Cancer Association Company Limited.

Amounts falling due after more than one year:

	2022 €'000	2021 €'000
Instalments due under research and services grants payable	2,289	3,158

### 16. Grant commitments and provisions

	31/12/2022 €'000	31/12/2021 €'000
Balance at 1 January	5,797	4,273
New grants awarded	3,767	4,012
Grants unused	(52)	(39)
Grants disbursed	(2,970)	(2,449)
Balance at 31 December	6,542	5,797

**Classified as:**

Due within 1 year	4,253	2,639
Due after 1 year	2,289	3,158
Balance at 31 December	6,542	5,797

# Notes to the financial statements (continued)

## 17. Financial instruments

The carrying values of the Society's financial assets and liabilities are summarised by category below:

	2022 €'000	2021 €'000
<b>Financial assets</b>		
Measured at fair value through profit or loss		
Current asset listed investments (see Note 13)	6,664	8,142
Measured at undiscounted amount receivable		
Trade and other debtors (see Note 14)	700	326
<b>Total</b>	<b>7,364</b>	<b>8,468</b>
<b>Financial liabilities</b>		
Measured at undiscounted amount payable		
Trade and other payables (see Notes 15 and 16)	7,269	6,286

The Society's income, expense, gains and losses in respect of financial instruments are summarised below:

	2022 €'000	2021 €'000
<b>Fair value gains and (losses)</b>		
On financial assets measured at fair value through statement of financial activity	(1,537)	891

## 18. Cash flow statement

### a) Reconciliation of changes in net income to cash generated by operations

	2022 €'000	2021 €'000
<b>Net income for the financial year</b>	<b>(1,998)</b>	4,423
<b>Adjustments for:</b>		
Depreciation	461	441
Loss on disposal of fixed assets	7	-
Increase in creditors	1,142	1,312
Decrease/(increase) in stock	63	(35)
(Increase)/decrease in debtors	(588)	525
Cash generated by operations	913	6,666

### b) Net debt

The Society had no borrowings or obligations under finance leases as at 31 December 2022 (2021: none).

# Notes to the financial statements (continued)

---

## 19. Retirement benefit schemes

### Defined Contribution Scheme

The Society operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the organisation in an independently administered fund. The organisation made contributions of €572,716 (2021: €463,394) during the financial year. The amount outstanding at the financial year end was €98,585 (2021: €91,029). The outstanding balances are held on the Balance Sheet under creditors.

## 20. Constitution

The liability of the members of the Society to contribute towards its assets is limited to an amount not to exceed the sum of €1.27 in each case.

## 21. Operating leases

### The future minimum lease payments under operating leases for each of the following periods:

At 31 December the Society had total commitments under operating leases in relation to charity shops premises, storage and office space:

	2022 €'000	2021 €'000
Within one year	563	589
Between one and five years	1,104	1,546
More than five years	118	240
<b>Total</b>	<b>1,785</b>	<b>2,375</b>

## 22. Financial assets

The Society's subsidiary, Irish Cancer Society Research Limited, was incorporated in Ireland in 1991 and the address of its registered office is 43-45 Northumberland Road, Dublin 4. Irish Cancer Society Research Limited was engaged in the business of sale of Christmas cards. The Company ceased trading at the end of 2013. As Irish Cancer Society Research Limited did not trade during 2022 and has insignificant net assets, consolidated financial statements have not been prepared.

## 23. Related parties

There were no related party transactions in 2022.

## 24. Comparatives

Certain prior year amounts have been reclassified for consistency with the current year presentation.



# Notes to the financial statements (continued)

---

## **25. Post balance sheet events**

There have been no events subsequent to the year-end that require any adjustment to, or additional disclosure in, the 2022 financial statements.

## **26. Political donations**

The Society made no political donations during 2022.

## **27. Approval of financial statements**

These financial statements were approved by the Board on May 4, 2023.

# Reference and administrative details

---

## Reference

Within this document the Irish Cancer Society is referred to as the Society and the Company.

## Company Number

20868

## Charity Regulator Number

20009502

## Revenue Charity Number

5863

## Registered Office

43/45 Northumberland Road, Dublin 4

## Company Directors

Dr. Sinead Brennan

Kieran Crowley (resigned 15th September 2022)

Prof. Liam Grogan

Brid Horan

Dr. Cormac Kilty

Irene O’Gorman

Ger Penny

Alex White

Allan Kearns

Dr. Mary Canavan

Maria Fleming (appointed 1st September 2022)

## Chair

Brid Horan

## Chief Executive

Averil Power

## Company Secretary

Conor King (resigned 4 March 2022)

Emma Browne (appointed 4 March 2022)

## Bankers

AIB Bank, 9 Terenure Road, Rathgar, Dublin 6

## Solicitors

Hayes Solicitors, Lavery House, Earlsfort Terrace, Dublin 2

## Investment Advisers

Brewin Dolphin Wealth Management Limited, 3 Richview Office Park, Clonskeagh, Dublin 14

## Auditors

Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, Deloitte and Touche House, Earlsfort Terrace, Dublin 2





Garden of Hope for  
Daffodil Day 2022



**Irish Cancer Society**  
43/45 Northumberland Road  
Dublin 4, Ireland

**T:** +353 (01) 231 0500  
**E:** [info@irishcancer.ie](mailto:info@irishcancer.ie)

